Curriculum Vitae s90
Total Page：16
File Type：pdf, Size：1020Kb
Date of Preparation: August 13, 2014
CURRICULUM VITAE
NAME: Ronald Frederick Pfeiffer, M.D. BIRTHDATE: August 11, 1947 BIRTHPLACE: Racine, Wisconsin SOCIAL SECURITY NO: ********* MARTIAL STATUS: Married (Brenda) CHILDREN: Two (Aaron, Gretchen)
EDUCATION:
1961-1965 Concordia High School, Seward, Nebraska 1965-1969 University of Nebraska, Lincoln, Nebraska Bachelor of Science (Phi Beta Kappa) 1969-1973 University of Nebraska Medical Center, Omaha, Nebraska Doctor of Medicine 1973-1977 Walter Reed Army Medical Center, Washington, D.C. Medicine Internship 1973-1974 Neurology Residency 1974-1977 Sept - Oct 1972 Guest Predoctoral Fellow Laboratory of Preclinical Pharmacology (Dr. E. Costa) National Institute of Mental Health 1975.1977 Guest Fellow Experimental Therapeutics Branch (Dr. D.B. Calne) National Institute of Neurological Diseases and Stroke National Institutes of Health
HONORS AND AWARDS:
1969 Phi Beta Kappa (elected)
1972 SAMA-UTMB Forum, Roche Award (2nd Place)
1982 Graduate Faculty, University of Nebraska
1984-1985 President, Nebraska Academy of Neurologists & Neurosurgeons
1988 American Neurological Association (elected)
1988 Co-Chairman, Session: Movement Disorders IV American Academy of Neurology Meeting, Cincinnati, OH
1989, 1993, 1996, Examiner, American Board of Psychiatry and Neurology 1997, 1998, 2001
1991 Co-Chairman, Session: Movement Disorders: Parkinsonism American Academy of Neurology Meeting, Boston, MA
1993 Lutheran of the Year - Lutherans of Greater Omaha
1994 Co-Chairman, Breakfast Seminar: Autonomic Disturbances in Parkinson’s Disease, 3rd International Congress of Movement Disorders, Orlando, FL RFPfeiffer
1995 Director, After Dinner Seminar: Gastrointestinal Dysfunction in Neurological Disease, American Academy of Neurology Meeting, Seattle, WA
1996 Director, Breakfast Seminar: Gastrointestinal Dysfunction in Neurological Disease, American Academy of Neurology Meeting, San Francisco, CA
1998 Co-Director, Breakfast Seminar: Wilson's Disease. Fifth International Conference of Parkinson's Disease and Movement Disorders, New York NY
1998-2001 Secretary/Treasurer, Movement Disorders Section, American Academy of Neurology
1999 Reviewer, Movement Disorders Review Session, American Academy of Neurology Meeting, Toronto ON
1999 Co-Director, Breakfast Seminar: Parkinson's Disease in the Young Robust. XIII International Congress on Parkinson's Disease. Vancouver, B.C., Canada.
2000 Co-Chairman, Session: Movement Disorders - Tremor, American Academy of Neurology Meeting, San Diego, CA.
2000 Reviewer, Movement Disorders Review Session, American Academy of Neurology Meeting, San Diego, CA.
2000 Member, Disease Council on Parkinson's Disease
2000 Participant: Forming Life; Forming Youth Conference 75th Anniversary Founders Weekend Valparaiso University
2001 Doctor of Laws - Concordia University - Nebraska
2001 Director, Dinner Seminar: Non-Motor Dysfunction in Parkinson’s Disease. American Academy of Neurology Meeting, Philadelphia, PA
2001 Vice Chair, Symposium: Swallowing and Gastrointestinal Function, World Congress of Neurology, London UK
2002 Director, Dinner Seminar: Non-Motor Dysfunction in Parkinson’s Diseases. American Academy of Neurology Meeting, Denver, CO.
2003-2004 Chairman, Nominating Committee, Parkinson Study Group
2003-present Member, Research Committee on Parkinsonism and Related Disorders, World Federation of Neurology (now the International Association of Parkinsonism and Related Disorders)
2004-2010 Chairman, Continuing Medical Education Committee,
2 RFPfeiffer
Movement Disorder Society
2004 Co-Director, Session: Autonomic Nervous System Function in Neurodegenerative Disease. 8th International Congress of Parkinson’s Disease and Movement Disorders, Rome, Italy
2005 Keynote Speaker, 25th Annual Frank N. Low Research Day University of North Dakota School of Medicine & Health Science
2005 Co-Chairman, Session: Movement Disorders: Genetics and Pathophysiology of Parkinsonism. American Academy of Neurology Meeting, Miami, FL
2005 Co-Presenter, Movement Disorders Highlights Session, American Academy of Neurology Meeting, Miami, FL
2005-2008 Member, Executive Committee, Parkinson Study Group
2005-2013 Member, Education Committee, WE MOVE
2005-2009 Member, Center Review Board, National Parkinson Foundation
2006 Reviewer, Clinical Discovery Award Program, Michael J. Fox Foundation
2006-2012 Chairman, Nominating Committee, Research Committee on Parkinsonism and Related Disorders, World Federation of Neurology
2006-2010 Member, Movement Disorder Society International Congress Scientific Program Committee: 11th Congress - Chicago, 2008 12th Congress - Paris, 2009 13th Congress - Buenos Aires, 2010
2007 Seeds of Hope Award, Wheat Ridge Ministries
2007-2008 Chairman, Nominating Committee, Parkinson Study Group 2008 Reviewer, Cognitive Deficits and Mood Disorders in Parkinson’s Disease Award Program, Michael J. Fox Foundation
2008-2010 Member, Site Selection Committee, Parkinson Study Group
2009-2012 Member, Scientific Review Committee, Parkinson Study Group
2009-2012 Chair, Other Non-motor Subgroup, NINDS Parkinson’s Disease Common Element Working Group
2009-present Member, Clinical and Scientific Advisory Board, National Parkinson Foundation
2010-2012 Vice Chair/Chair Elect, Movement Disorders Section, American Academy of Neurology
3 RFPfeiffer
2009-2013 Member, Education Committee, Movement Disorder Society
2010 Chair, Session: Non-Motor Symptoms, 2nd World Parkinson Congress, Glasgow, Scotland, UK
2010-present Chair, Clinical Study Oversight Committee, Parkinson’s Progression Markers Initiative (PPMI)
2011 Co-Chair, Session: Movement Disorders: Neuroimaging and Parkinson’s Disease, 63rd American Academy of Neurology Annual Meeting, Honolulu, HI
2011 Chair, Session: Autonomic Dysfunction, XIth Symposium on Parkinson’s Disease: Targeting Non-Motor Symptoms, Arlington, VA
2011 Moderator, Session: Autonomic Dysfunction Panel discussion, XIth Symposium on Parkinson’s Disease: Targeting Non-Motor Symptoms, Arlington, VA
2011 Chairperson, Hirotaro Narabayashi Symposium: From Pathology to Diagnosis, XIX World Congress on Parkinson’s Disease and Related Disorders, Shanghai, China
2011 Chairperson, Educational Session: XIX World Congress on Parkinson’s Disease and Related Disorders, Shanghai, China
2012 Co-Chair, Session: Parkinson’s Disease: Non-Motor Symptoms, 64th American Academy of Neurology Annual Meeting, New Orleans, LA
2012-present Chair, Movement Disorders Section, American Academy of Neurology
2012-present Member, Scientific Advisory Board, International Congress on Mental Dysfunction and Other Non-Motor Features in Parkinson’s Disease and Related Disorders: 8th Congress, Berlin, Germany, 2012 9th Congress, Seoul, Korea, 2012 10th Congress, Nice, France, 2014
2012 Co-Chair, Session: Progression of Nonmotor Symptoms, 8th International Congress on Mental Dysfunction and Other Non-Motor Features in Parkinson’s Disease and Related Disorders, Berlin, Germany
2012 Co-Chair, Session: Olfactory Function in Parkinson’s Disease, 8th International Congress on Mental Dysfunction and Other Non-Motor Features in Parkinson’s Disease and Related Disorders, Berlin, Germany
2012 Member, Patient Education Task Force, Movement Disorder Society
2013 Director, Seminar: Bladder Leaks, Sweats, Drools, Sadness and Other Nonmotor Parkinson’s Disease Symptoms: How to Recognize and
4 RFPfeiffer
Treat? American Academy of Neurology Annual Meeting, San Diego, CA
2013 Co-Chair, Session: The Spectrum of Sexual Disorders in Parkinson’s Disease: From Hypo- to Hyper-Sexuality, 9th International Congress on Mental Disorders and Other Non-Motor Features in Parkinson’s Disease and Related Disorders Seoul, South Korea
2013 Chair, Session: Hallucinations and Related Phenomena in PD 3rd World Parkinson Congress Montreal, Canada
2013 Co-Chair, Plenary Session: George Cotzias Symposium – Emerging Conservative Strategies in Parkinson’s Disease 20th World Congress on Parkinson’s Disease and Related Disorders Geneva, Switzerland
2013 Co-Chair, Session: Parkinsonism and Related Disorders: A Summary and Discussion of the Best Scientific and Clinical Articles From 2012- 2013 20th World Congress on Parkinson’s Disease and Related Disorders Geneva,
2013 Co-Chair, Plenary Session: Lauri Laitinen Symposium – Emerging Neurosurgical Strategies in Parkinson’s Disease 20th World Congress on Parkinson’s Disease and Related Disorders Geneva, Switzerland
2014 Honorary Lifetime Member Pakistan Society of Neurology
COMMUNITY SERVICE:
2010-present Member, Personnel Committee, Concordia University-Nebraska Board of Regents 2007 Delegate, National Convention, Lutheran Church-Missouri Synod 2001-2010 Board of Regents, Concordia University-Nebraska 2001-2010 Board of Directors, Concordia University-Nebraska Foundation 1999-2006 Board of Directors, Wheat Ridge Ministries, Itasca, IL 1997-2009 Board of Education, Trinity Lutheran Church, Memphis, TN 1993-1994 Board of Directors, Northside Lutheran Church, Omaha, NE 1982, 1991-93 President, St. Paul Lutheran Church, Omaha, NE 1983-1988 Board of Directors, Lutheran Tape Ministry, Omaha NE 1987-1990 President, Christian Day School Board, St. Paul Lutheran Church, Omaha, NE 1987-1990 Board of Directors, Midlands Chapter, National Multiple Sclerosis Society 1988-1992 Director, American Parkinson’s Disease Association Information and Referral Center, University of Nebraska Medical Center
MILITARY SERVICE:
5 RFPfeiffer
United States Army 1972-1973 University of Nebraska Medical Center 1973-1977 Walter Reed Army Medical Center, Washington, D.C. 1977-1979 U.S. Army Hospital, Nuremberg Germany 1979-1980 U.S. Army Hospital, Landstuhl Germany
BOARD CERTIFICATION:
American Board of Psychiatry and Neurology - 1979
MEDICAL LICENSURE:
State of Nebraska - #14142 (inactive) State of Tennessee-MD#25898
SOCIETY MEMBERSHIPS:
1994-2006 Tennessee Medical Association 1994-2006 Memphis and Shelby County Medical Society 1988-present American Neurological Association 1975-present American Academy of Neurology 1986-present Parkinson Study Group 1986-present Movement Disorder Society 1986-2005 Society for Neuroscience 1994-97; 2000-2001 American Medical Association 1985-1992 Central Society for Neurological Research 1980-1994 Nebraska Academies of Neurologists & Neurosurgeons 1986-1994 Omaha Mid-West Clinical Society 1987-1993 Association of University Professors of Neurology
UNIVERSITY APPOINTMENTS
1996-present University of Tennessee Health Science Center Vice Chair, Neurology 1994-present University of Tennessee Health Science Center Professor, Neurology 1993-1994 University of Nebraska College of Medicine Professor of Internal Medicine (Neurology) Professor of Pharmacology 1987-1993 University of Nebraska College of Medicine Chief, Section of Neurology 1987-1993 University of Nebraska College of Medicine Associate Professor of Internal Medicine (Neurology) Associate Professor of Pharmacology 1985-1986 University of Nebraska College of Medicine Associate Professor of Neurology and Associate Professor of Pharmacology 1980-1985 University of Nebraska College of Medicine Assistant Professor of Neurology Assistant Professor of Pharmacology 1985-1994 Creighton University School of Medicine (Courtesy) Associate Professor of Neurology 1986- 1989 Creighton University School of Medicine (Courtesy)
6 RFPfeiffer
Interim Chairman, Department of Neurology 1980-1985 Creighton University School of Medicine (Courtesy) Assistant Professor of Neurology
HOSPITAL APPOINTMENTS:
1994-present The Regional Medical Center Memphis, Tennessee 1994-present Veteran’s Administration Hospital Memphis, Tennessee 1994-2009 Methodist University Hospital Memphis, Tennessee 1994-2004 University of Tennessee, William A. Bowld Hospital Memphis, Tennessee 1994-2002 Baptist Memorial Hospital Memphis, Tennessee 1989-1994 Clarkson Memorial Hospital Omaha, Nebraska 1987-1994 Veteran’s Administration Hospital Omaha, Nebraska 1983-1987 Methodist Hospital Omaha, Nebraska 1980-1985 Veteran’s Administration Hospital Omaha, Nebraska 1980-1994 St. Joseph Hospital Omaha, Nebraska 1980-1994 University of Nebraska Hospital Omaha, Nebraska
PRACTICE (PROFESSIONAL) EXPERIENCE:
2013-present Attending Neurologist University of Tennessee, Department of Neurology, 855 Monroe Avenue, Suite 415, Memphis, TN 38163 Regional Medical Center 877 Jefferson Avenue, Memphis, TN 38104 Wesley Neurology Clinic 1211 Union Avenue, Suite 400, Memphis, TN 38104
1999-2013 Attending Neurologist University of Tennessee, Department of Neurology, 855 Monroe Avenue, Suite 415, Memphis, TN 38163 Regional Medical Center 877 Jefferson Avenue, Memphis, TN 38104 Semmes-Murphey Neurologic and Spine Institute 1325 Eastmoreland Avenue, Memphis, TN 38104
1994-1999 Attending Neurologist University of Tennessee, Department of Neurology VA Medical Center
7 RFPfeiffer
Semmes-Murphey Clinic Memphis, TN
1980-1994 Attending Neurologist University of Nebraska Medical Center Omaha, NE
1979-1980 Attending Neurologist Landstuhl Army Medical Center Landstuhl, Germany
1977-1979 Attending Neurologist U.S. Army Hospital Nuremberg, Germany
TEACHING EXPERIENCE: TEACHING ACTIVITIES 2008 - PRESENT
Course Lectures (University of Tennessee):
DATE COURSE AUDIENCE TITLE
8/15/08 Neurological Neurology Residents Examination of the Emergencies Extrapyramidal Motor System 8/19/08 Neuroscience M2 Students Hypokinetic Movement Disorders 8/19/08 Neuroscience M2 Students Hyperkinetic Movement Disorders 8/22/08 Neurological Neurology Residents Movement Disorder Emergencies Emergencies
9/02/09 Neuroscience M2 Students Movement Disorders (2 hours)
9/14/09 Neurological Neurology Residents Movement Disorder Emergencies Emergencies 9/23/10 Noon Conference Internal Medicine Residents Parkinson’s Disease
08/05/11 Neurological Neurology Residents Movement Disorder Emergencies Emergencies and Gait Abnormalities
01/16/14 Neuroscience M2 Students Movement Disorders
06/02/14 Noon Conference Internal Medicine Residents Drug-Induced Movement Disorders 08/06/14 Neurological Neurology Residents Emergencies Movement Disorder Emergencies
8 RFPfeiffer
Continuing Education Lectures (University of Tennessee):
DATE GROUP LOCATION TITLE
1/11/08 Neurology Grand Rounds UTHSC Parkinson’s Disease and Nonmotor Dysfunction
9/26/08 Neurology Grand Rounds UTHSC Evolution of Parkinson’s Disease Therapy
2/20/09 Neurology Grand Rounds UTHSC Normal Pressure Hydrocephalus
3/13/09 Neurology Grand Rounds UTHSC Prescription Prescribing Practices
4/17/09 Neurology Grand Rounds UTHSC Autonomic Dysfunction in Parkinson’s Disease 01/08/10 Neurology Grand Rounds UTHSC Neurogastroenterology: A View from Both Ends
2/19/10 Neurology Grand Rounds UTHSC Neurogenic Dysphagia
12/17/10 Neurology Grand Rounds UTHSC Drug-Induced Movement Disorders
09/16/11 Neurology Grand Rounds UTHSC Behavioral Dysfunction in Parkinson’s Disease
09/30/11 Neurology Grand Rounds UTHSC Autonomic Dysfunction in Parkinson’s Disease
10/28/11 Neurology Grand Rounds UTHSC Neurologic Manifestations of Malabsorption Syndromes
06/01/12 Neurology Grand Rounds UTHSC Sleep in Parkinson’s Disease
09/07/12 Neurology Grand Rounds UTHSC Parkinson’s Disease: Where Does It Start? How Does It Spread?
11/02/12 Neurology Grand Rounds UTHSC Orthostatic Tremor
09/13/13 Neurology Grand Rounds UTHSC Wilson’s Disease
01/10/14 Neurology Grand Rounds UTHSC Emerging Pharmacotherapeutic Strategies in the Treatment of Parkinson’s Disease
01/17/14 Neurology Grand Rounds UTHSC Behavioral Changes in Parkinson’s Disease
Wilson’s Disease 08/08/14 Neurology Grand Rounds UTHSC
Lay Group Lectures:
9 RFPfeiffer
DATE GROUP LOCATION TITLE 2/12/08 Parkinson Association of Naples, FL Parkinson’s Disease and Nonmotor Southwest Florida Dysfunction Annual symposium
5/27/08 PD Support group Memphis Research Update
7/18/08 Parkinson’s Disease Lansing, MI Autonomic Dysfunction in PD Foundation Symposium: Mind, Mood and Body: Understanding Nonmotor Symptoms of PD
9/20/08 Parkinson Center of Oregon Portland, OR Evolution of Parkinson’s Disease Therapy 25th Annual Symposium
10/4/08 14th Annual UT Parkinson’s Memphis, TN Evolution of Parkinson’s Disease Therapy Disease Symposium
11/7/08 3rd Annual Southeastern Rome, GA Parkinson’s Disease and Nonmotor Parkinson’s Disease Dysfunction Conference
11/14/08 APDA New England Sturbridge, MA Recognizing and Treating Non-Motor Issues Regional Parkinson’s (in Parkinson’s Disease) Conference
5/9/09 Annual Meeting, Parkinson Vancouver, BC, Sleep and Behavioral Disorders in Society of British Columbia Canada Parkinson’s Disease
6/20/09 APDA Mississippi Chapter Greenwood, MS What’s on the Horizon for PD? 2nd Annual Parkinson’s Disease Conference
10/03/09 15th Annual UT Parkinson’s Memphis, TN Research Directions in PD: Hope on the Disease Symposium Horizon?
10 RFPfeiffer
10/10/09 Southeastern Parkinson’s Rome, GA Nonmotor Symptoms in Parkinson’s Disease Disease Conference
11 RFPfeiffer
10/31/09 Edward I. Rudman Boston, MA Survey of Nonmotor Aspects of Parkinson’s Parkinson’s Disease and Disease Caregiver Symposium, Beth Israel Deaconess Medical Center – Harvard Medical School
05/22/10 16th Annual UT Parkinson’s Memphis, TN Behavioral Dysfunction in Parkinson’s Disease Symposium Disease
PD Support Group 1/25/11 Memphis, TN Autonomic Dysfunction in Parkinson’s Disease 17th Annual UT Parkinson’s 05/07/11 Disease Symposium Memphis, TN Autonomic Dysfunction in Parkinson’s Disease Midwest PD Conference and Young Onset PD Conference 06/18/11 Des Moines, IA Managing Gastrointestinal Issues in 5th Annual University of Parkinson’s Disease Kansas Medical Center PD Symposium 08/20/11 Kansas City, KS Recognition and Treatment of Nonmotor 6th Annual Southeastern PD Symptoms of Parkinson’s Disease Conference
10/06/11 18th Annual Parkinson’s Atlanta, GA Parkinson’s Disease and Nonmotor Disease Symposium Dysfunction
05/19/12 Annual Symposium, Grand Memphis, TN Sleep in Parkinson’s Disease Traverse PD Support Group
06/07/12 20th Annual University of Traverse City, MI Gastrointestinal Dysfunction in Parkinson’s Southern California Disease Parkinson’s Disease Update
12/01/12 Movement Disorders Forum Pasadena, CA Parkinson’s Disease and Nonmotor Dysfunction
02/09/13 Savannah, GA Parkinson’s Disease and Nonmotor Dysfunction
12 RFPfeiffer
05/04/13 19th Annual Parkinson’s Memphis, TN Treatment of Parkinson’s Disease Disease Symposium
10/25/13 Center on Aging Northeast Paragould, AR New Strategies in Treating Parkinson’s Disease 21st Annual University of 12/14/13 Southern California Pasadena, CA Behavioral Changes in Parkinson’s Disease Parkinson’s Disease Update
Course Organizer/Supervisor:
09/15/95 1st Annual UT Parkinson’s Disease Symposium Memphis, TN 09/20/96 2nd Annual UT Parkinson’s Disease Symposium Memphis, TN 09/19/97 3rd Annual UT Parkinson’s Disease Symposium Memphis, TN 09/18/98 4th Annual UT Parkinson's Disease Symposium Memphis, TN 10/30/99 5th Annual UT Parkinson's Disease Symposium Memphis, TN 10/28/00 6th Annual UT Parkinson’s Disease Symposium Memphis, TN 11/17/01 7th Annual UT Parkinson’s Disease Symposium Memphis, TN 10/05/02 8th Annual UT Parkinson’s Disease Symposium Memphis, TN 09/27/03 9th Annual UT Parkinson’s Disease Symposium Memphis, TN 10/16/04 10th Annual UT Parkinson’s Disease Symposium Memphis, TN 10/08/05 11th Annual UT Parkinson’s Disease Symposium Memphis, TN 10/21/06 12th Annual UT Parkinson’s Disease Symposium Memphis, TN 10/20/07 13th Annual UT Parkinson’s Disease Symposium Memphis, TN 10/04/08 14th Annual UT Parkinson’s Disease Symposium Memphis, TN 10/03/09 15th Annual UT Parkinson’s Disease Symposium Memphis, TN 05/22/10 16th Annual UT Parkinson’s Disease Symposium Memphis, TN 05/07/11 17th Annual UT Parkinson’s Disease Symposium Memphis, TN 05/19/12 18th Annual UT Parkinson’s Disease Symposium Memphis, TN 05/04/13 19th Annual UT Parkinson’s Disease Symposium Memphis, TN 06/28/14 20th Annual UT Parkinson's Disease Symposium Memphis, TN
EDITORIAL APPOINTMENTS:
Co-Editor in Chief:
Parkinsonism and Related Disorders, 2008-present
Editorial Boards:
International Journal of Brain Science, 2013-present Conference Papers in Medicine, 2012-present Journal of Parkinson’s Disease, 2011-present Parkinsonism and Related Disorders, 2005-2008 Movement Disorders, 1996-2000 NeuroNews, 1988-1993
Reviewer For:
13 RFPfeiffer
. Acta Neurologica Scandinavica, 2006, 2013, 2014 . Acta Physiologica, 2013, 2014 . AHFS Drug Information, 1998 . American Journal of Gastroenterology, 1992, 2001, 2002 . Annals of Neurology, 1997, 1998, 2000, 2001, 2002, 2003, 2004, 2005 . Autonomic Neuroscience: Basic and Clinical, 2011 . BioMed Research International, 2014 . Case Reports in Psychiatry, 2014 . Clinical Autonomic Research, 2000, 2001, 2004, 2005, 2006 . Clinical Neuropharmacology, 2006 . Clinical Science, 1993 . CNS Drugs, 2000, 2005, 2007, 2008 . European Journal of Neurology, 2006, 2008, 2009, 2011 . Experimental Neurology, 1998 . Expert Opinion on Drug Delivery, 2005, 2008, 2009 . Expert Review of Neurotherapeutics, 2006, 2009 . Future Neurology, 2006 . Helicobacter, 2008 . Journal of the American Geriatric Society, 1995, 1996, 1997, 1998, 2000 . Journal of Geriatric Psychiatry and Neurology, 2002 . Journal of Molecular Neuroscience, 2011 . Journal of Neurochemistry, 2014 . Journal of the Neurological Sciences, 2011 . Journal of Neurology, 2006, 2012, 2013 . Journal of Neurology, Neurosurgery and Psychiatry, 1999, 2007, 2009 . Journal of Neuroscience, 1999 . Journal of Parkinson's Disease, 2013 . Journal of Stroke and Cerebrovascular Diseases, 2008 . Lancet, 2002 . Lancet Infectious Diseases, 2008 . Lancet Neurology, 2003, 2004, 2007, 2008 . Mayo Clinic Proceedings, 2010 . Mental Retardation and Developmental Disabilities Research Reviews, 1997 . Movement Disorders, 1992, 1993, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2012, 2013, 2014 . Neurobiology of Disease, 2011 . Neurodegenerative Disease Management, 2014 . Neurogastroenterology and Motility, 2008, 2009 . Neurology, 1988, 1989, 1990, 1991, 1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2009, 2010, 2011, 2012, 2013, 2014 . Neuroscience, 2007, 2008 . Neuroscience Letters, 2012 . Parkinsonism and Related Disorders, 2005, 2006, 2007, 2008, 2010, 2011, 2012, 2014 . Parkinson’s Disease, 2011, 2014 . Pharmacological Reviews, 1995, 1999 . PLOS ONE, 2013 . Progress in Neuropsychopharmacology, 2005 . Stroke, 2010
PUBLICATIONS:
14 RFPfeiffer
Books, Monographs:
1. Pfeiffer RF, Quigley EMM (Guest Editors): Neurogastroenterology. Seminars in Neurology, December 1996.
2. Bodis-Wollner I, Pfeiffer RF (eds). Non-Motor Dysfunction in Parkinson's Disease. Clinical Neuroscience Vol 5, Number 2, 1998 (Published in 2000)
3. Quigley EMM, Pfeiffer RF (eds). Neurogastroenterology. Butterworth- Heinemann:Philadelphia, 2004.
4. Pfeiffer RF, Bodis-Wollner I (eds). Parkinson’s Disease and Non-Motor Dysfunction. Humana Press:Totowa, NJ, 2005.
5. Ebadi M, Pfeiffer RF (eds). Parkinson’s Disease. CRC Press:Boca Raton, FL, 2005.
6. Pfeiffer RF, Wszolek ZK, Ebadi M (eds). Parkinson’s Disease (Second Edition). Taylor & Francis CRC Press:Boca Raton, FL, 2013.
7. Pfeiffer RF, Bodis-Wollner I (eds). Parkinson’s Disease and Non-Motor Dysfunction (Second Edition). Humana Press/Springer:New York, 2013.
Chapters in Books:
1. Ebadi M, Pfeiffer RF, Lacy PS, Davis RH: The catalytic role of pyridoxal phosphate and the regulatory involvement of pyridoxal kinase in the metabolism of monoamines. In: Yahr MD (ed.): Treatment of Parkinsonism – The Role of Dopa Decarboxylase Inhibitors (Advances in Neurology, Volume 2). Raven Press:New York. pp. 199-227, 1973.
2. Teychenne PF, Pfeiffer RF, Kartzinel R, Calne DB: Long-term experience with bromocriptine in parkinsonism. In: Bayliss RIS, Turner P, Macky WP (eds.): Pharmacologic and Clinical Aspects of Bromocriptine. Turnbridge Wells, England, MCS Consultants. pp. 27-33, 1976.
3. Calne DB, Teychenne PF, Pfeiffer RF: Treatment of parkinsonism. In: Messiha FS, Kenny AD (eds.): Parkinson's Disease. Neurophysiological, Clinical, and Related Aspects. Plenum Press:New York. pp. 49-61, 1977.
4. Williams AC, Nutt J, Lake CR, Pfeiffer RF, Teychenne PF, Ebert M, Calne DB: Actions of bromocriptine in the Shy-Drager and Steele-Richardson-Olszewski syndromes. In: Fuxe K, Calne DB (eds.): Dopaminergic Ergot Derivatives and Motor Function. Pergamon Press:New York. pp. 271-283, 1979.
5. Ebadi M, Pfeiffer RF: Zinc in neurological disorders and in experimentally-induced epileptiform seizures. In: Frederickson CJ, Howell GA, Kasarskis EJ (eds.): Neurobiology of Zinc, Part B: Deficiency, Toxicity, and Pathology. Alan R. Liss Inc:New York. pp. 307-324, 1984.
6. Pfeiffer RF, Wilken KE, Glaeske CS: Mesulergine: 18 months' experience. In: Fahn S, Marsden CD, Jenner P, Teychenne P (eds.): Recent Developments in Parkinson's Disease. Raven Press:New York. pp. 355-361, 1986.
15 RFPfeiffer
7. Pfeiffer RF, Hsieh HH, Diercks MJ, Glaeske C, Jefferson A, Cheng S.-C.: Dexamethasone suppression test in Parkinson's disease. In: Yahr MD, Bergmann KJ (eds.): Parkinson’s Disease (Advances in Neurology, Volume 45). Raven Press:New York. pp. 439-442, 1986.
8. Shoulson I, and the Parkinson Study Group: Antioxidative experimental strategies aimed at slowing the progression of Parkinson's disease. Proceedings of the International Symposium on Alzheimer's Disease, June 12-15, 1988, Kuopio, Finland (World Federation of Neurology Research Group on Dementia). Publication of the University of Kuopio (ISBN 951-780-488-1), pp. 35-36, 1988.
9. Pfeiffer RF, Murrin LC: D1 receptor agonists in Parkinson's disease. In: Koller W, Paulson G (eds.): Therapeutic Approaches to Parkinson's Disease. Marcel Dekker:New York. pp. 333-344, 1990.
10. Shoulson I, and the Parkinson Study Group: Effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease: a preliminary report. In: Rinne UK, Heinonen E (eds.): Neuroprotective Therapy in Early Parkinson's Disease. Orion Corp., Farmos, Turku, Finland. pp 25-32, 1991.
11. Ebadi M, Pfeiffer RF, Murrin LC: Neuroleptic-induced movement disorders. In: Osborne NN (ed.): Current Aspects of the Neurosciences, Volume 4. pp. 159-203, 1992.
12. Pfeiffer RF, Ebadi M: Wilson's disease. In: Stern MB, Koller WC (eds.): Parkinsonian Syndromes. Marcel-Dekker:New York. pp. 321-340, 1993.
13. Wszolek ZK, Pfeiffer RF: Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration. In: Stern MB, Koller WC (eds.): Parkinsonian Syndromes. Marcel-Dekker:New York. pp. 297-312, 1993.
14. Ebadi M, Blaxall HS, Cerutis DR, Bylund DB, Prapapanich V, Heck DA, Pfeiffer RF: Molecular Characterization and Actions of the Alpha-2 Adrenergic Receptor Subtype A/D in the Pineal Gland. In: Moller M, Povet P (eds.): Advances in Pineal Research. John Libbey Press:London. pp 197-205, 1994.
15. Ebadi M, Hao R, Cerutis DR, Blaxall HS, Pfeiffer RF, Rodriguez-Sierra JF, Norgren RB, Strauss J, El Sayed MA: Zinc, Metallothionein, Zinc Fingers, and Neurotrophic Activity in Neuroimmunoendocrine System. In: Gupra D, Wollman HA, Fedor-Freyberg A (eds): Pathophysiology of Immune-Neuroendocrine Communication Circuit. Mattes Verlag:Heidelberg. pp 11-47, 1994.
16. Pfeiffer RF, Murrin LC: D1 receptor agonists in Parkinson’s disease. In: Koller W, Paulson G (eds): Therapeutic Approaches to Parkinson’s Disease (Second Edition). Marcel Dekker:New York. pp 261-271, 1995.
17. Pfeiffer RF, Ebadi M: Pharmacologic management of Parkinson's disease. In: Weiner WJ, Cohen AM (eds.): Interdisciplinary Treatment of Parkinson's Disease. Demos:New York. pp 9-38, 1995.
18. Pfeiffer RF, Quigley EMM, Edwards LL: Gastrointestinal Dysfunction in Neurologic Disease. In: Korczyn AD (ed): Handbook of Autonomic Nervous System Dysfunction. Marcel Dekker:New York. pp 311-339, 1995.
19. Gasser T, Wszolek Z, Supala A, Trofatter J, Ozelius L, Uitti RJ, Pfeiffer RF, Gusella J, Calne D, Breakefield XO: Genetic Linkage Studies in Autosomal Dominantly Inherited L-Dopa
16 RFPfeiffer
Responsive Parkinsonism. Evaluation of Candidate Genes. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds): Parkinson’s Disease (Advances in Neurology, Volume 69). Lippincott- Raven:Philadelphia. pp 87-95, 1996.
20. Pfeiffer RF: Parkinson’s Disease. In: Rakel R (ed): Conn’s Current Therapy, 1997. WB Saunders:New York. pp 963-972, 1997.
21. Pfeiffer RF: Neurodiagnostic Tests of Degenerative Diseases. In: Corazziari E (ed): NeUroGastroenterology. W. de Gruyter:Berlin. pp 199-206, 1996.
22. Wszolek ZK, Pfeiffer RF: Hereditofamilial Disorders. In: Watts R, Koller W. (eds.): Movement Disorders: Neurologic Principles and Practice. McGraw-Hill:New York. pp 351- 363, 1997.
23. Pfeiffer RF: Wilson’s Disease. In: Watts R, Koller W. (eds.): Movement Disorders: Neurologic Principles and Practice. McGraw-Hill:New York. pp 623-637, 1997.
24. LeWitt P, Pfeiffer R: Neurological Aspects of Wilson’s Disease: Clinical Manifestations and Treatment Considerations. In: Jankovic J, Tolosa E (eds): Parkinson’s Disease and Movement Disorders (Third Edition). Williams and Wilkins:Baltimore. pp 377-399, 1998.
25. Pfeiffer R: Clinical Management of Parkinson's Disease. In: Marwah J, Teitelbaum H (eds): Parkinson's Disease (Advances in Neurodegenerative Disorders, Volume 1). Prominent Press:Scottsdale. pp 1-49, 1998.
26. Shoulson I, and the Parkinson Study Group: DATATOP: A Decade of Neuroprotective Inquiry. In: Olanow CD, Jenner P (eds): Beyond the Decade of the Brain: Neuroprotection in Parkinson’s Disease, Volume 3. Wells Medical Ltd:Kent, UK. pp 319-329, 1998.
27. Ebadi M, Hiramatsu M, Ramana Kumari MV, Hao R, Pfeiffer RF: Metallothionein in Oxidative Stress of Parkinson’s Disease. In: Klaasen CD (ed): Metallothionein IV. Advances in Life Sciences. Birkhauser Verlag:Basel. pp 341-349, 1999.
28. Pfeiffer RF, Quigley EM: Gastrointestinal Motility Problems in Patients with Parkinson’s Disease. Epidemiology, Pathophysiology, and Guidelines for Management. In: Palmer KJ (ed): Drug Treatment Issues in Parkinson’s Disease. Adis Books: Auckland. pp. 131-146, 2000.
29. Pfeiffer RF, Hao R: Cerebrospinal Fluid Toxicity in Parkinson’s Disease. In: Factor SA, Weiner, WJ (eds): Parkinson’s Disease: Diagnosis and Clinical Management. Demos:New York. pp 329-337, 2002.
30. Lewitt P, Pfeiffer RF: Neurological Aspects of Wilson’s Disease: Clinical Manifestations and Treatment Considerations. In: Jankovic J, Tolosa E (eds): Parkinson’s Disease and Movement Disorders (Fourth Edition). Lippincott Williams & Wilkins:Philadelphia. pp 240-255, 2002.
31. Pfeiffer RF: Catechol-O-methyltransferase in Parkinson’s disease. In: Pahwa R, Lyons KE, Koller WC (eds): Handbook of Parkinson’s Disease (Third Edition). Marcel Dekker:New York. pp 437-451, 2003.
32. Pfeiffer RF, Quigley EMM: Gastrointestinal Dysfunction in Diseases of the Cerebral Hemispheres and Movement Disorders. In: Quigley EMM, Pfeiffer RF (eds): Neurogastroenterology. Elsevier:Philadelphia. pp 59-81, 2004.
17 RFPfeiffer
33. Pfeiffer RF: Gastrointestinal Dysfunction in Spinal Cord Disease. In: Quigley EMM, Pfeiffer RF (eds): Neurogastroenterology. Elsevier:Philadelphia. pp 101-112, 2004.
34. Pfeiffer RF: Parkinsonism. In: Rakel RE, Bope ET (eds): Conn’s Current Therapy, 2004. WB Saunders:New York. pp 989-995, 2004.
35. Pfeiffer RF: Neurogenic Dysphagia. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J (eds): Neurology in Clinical Practice (Fourth Edition). Elsevier:Philadelphia. pp 165-176, 2004.
36. Pfeiffer RF: Wilson’s Disease. In: Watts RL, Koller WC (eds): Movement Disorders. Neurologic Principles and Practice (Second Edition). McGraw-Hill:New York. pp. 779-797, 2004.
37. Pfeiffer RF: Intestinal Dysfunction. In: Pfeiffer RF, Bodis-Wollner I (eds): Parkinson’s Disease and Non-Motor Dysfunction. Humana Press:Totowa, NJ. pp. 115-125, 2005.
38. Ford B, Pfeiffer RF: Pain Syndromes and Disorders of Sensation. In: Pfeiffer RF, Bodis- Wollner I (eds): Parkinson’s Disease and Non-Motor Dysfunction. Humana Press:Totowa, NJ. pp. 255-267, 2005.
39. Pfeiffer RF: Gastrointestinal Dysfunction in Parkinson’s Disease. In: Ebadi M, Pfeiffer RF (eds): Parkinson’s Disease. CRC Press:Boca Raton, FL. pp. 259-273, 2005.
40. Pfeiffer RF: Neurotransplantation in Parkinson’s Disease. In: Ebadi M, Pfeiffer RF (eds): Parkinson’s Disease. CRC Press:Boca Raton, FL pp. 767-776, 2005.
41. Pfeiffer RF: The Phenotypic Spectrum of Parkinson’s Disease. In: LeDoux M (ed.): Animal Models of Movement Disorders. Academic Press:San Diego. pp. 127-137, 2005.
42. Pfeiffer RF: Neurology of Gastroenterology and Hepatology. In: Schapira AHV (ed.): Neurology and Clinical Neuroscience. Mosby/Elsevier:Philadelphia. pp. 1511-1524, 2007.
43. Pfeiffer RF: Bladder and Sexual Dysfunction. In: Schapira AHV (ed.): Neurology and Clinical Neuroscience. Mosby/Elsevier:Philadelphia. pp. 362-371, 2007.
44. Pfeiffer RF: Catechol-O-Methyltransferase Inhibitors. In: Pahwa R, Lyons K (eds): Handbook of Parkinson’s Disease (Fourth Edition). Taylor & Francis:New York. pp. 365- 378, 2007.
45. Lewitt P, Pfeiffer RF: Neurologic Aspects of Wilson’s Disease: Clinical Manifestations and Treatment Considerations. In: Jankovic J, Tolosa E (eds): Parkinson’s Disease & Movement Disorders (Fifth Edition).Lippincott Williams & Wilkins:Philadelphia. pp. 254-270, 2007.
46. Pfeiffer RF: Multiple System Atrophy. In: Melamed E, Koller W (eds): Parkinson’s Disease and Related Disorders, Part II (Handbook of Clinical Neurology). Elsevier:Philadelphia. pp. 307-326, 2007.
47. Pfeiffer RF: Consult for a Neurohepatologist. In: Reich S (ed): Movement Disorders: 100 Instructive Cases. Informa Healthcare:New York. pp. 261-264, 2008.
18 RFPfeiffer
48. Pfeiffer RF: and Shanahan F: Inflammatory Bowel Disease. In: Biller J (ed): Interface of Neurology and Internal Medicine. Lippincott Williams & Wilkins:Philadelphia. pp. 228- 232, 2008.
49. Pfeiffer RF: Neuroinflammation in Parkinson’s Disease. In: Factor SA, Weiner, WJ (eds): Parkinson’s Disease: Diagnosis and Clinical Management (Second Edition). Demos:New York. pp. 449-453, 2008.
50. Pfeiffer RF: Neurogenic Dysphagia. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J (eds): Neurology in Clinical Practice (Fifth Edition). Elsevier:Philadelphia. pp. 165-175, 2008.
51. Pfeiffer RF: Wilson’s Disease. In: Weiner W, Tolosa E (eds): Movement Disorders – Hyperkinetic (Handbook of Clinical Neurology). Elsevier:Edinburgh. pp. 681-709, 2011.
52. Pfeiffer RF: Gastrointestinal and Swallowing Disturbances in Parkinson’s Disease. In: Olanow W, Lang A, Stocchi F (eds): The Non-Motor and Non-Dopaminergic Features of Parkinson’s Disease. Blackwell Publishing:Oxford, UK. pp. 257-273, 2011.
53. Pfeiffer RF: Neurogenic Dysphagia. In: Daroff RB, Fenichel GM, Jankovic J, Mazziotta JC (eds): Bradley’s Neurology in Clinical Practice (Sixth Edition). Elsevier Saunders:Philadelphia. pp.153-163, 2012.
54. Pfeiffer RF: Wilson’s Disease. In: Watts RL, Obeso J, Standaert D (eds): Movement Disorders. Neurologic Principles and Practice (Third Edition). McGraw-Hill:New York. pp. 833-856, 2012.
55. Pfeiffer RF: Strength (and fun) in numbers: lessons from an “extended family” of Parkinson patients and their spouses. In: Fernandez HH, Merello M (eds). Movement Disorders: Unforgettable Cases and Lessons from the Bedside. Demos Medical:New York. pp. 29-30, 2012.
56. Bloomer RJ, Schilling BK, Hammond KG, LeDoux MS, Pfeiffer RF. Effect of resistance exercise training on biomarkers of oxidative stress in men and women with Parkinson’s disease. In: Reyes AM, Contreras CC (eds.). Handbook on Oxidative Stress. Nova Science Publishers:Commack, NY. pp. 469-478, 2012.
57. Pfeiffer RF: Gastrointestinal dysfunction in Parkinson’s disease. In: Pfeiffer RF, Wszolek ZK, Ebadi M (eds). Parkinson’s Disease (Second Edition). Taylor & Francis CRC Press:Boca Raton. pp. 309-326, 2013.
58. Pfeiffer RF: Intestinal Dysfunction. In: Pfeiffer RF, Bodis-Wollner I (eds). Parkinson’s Disease and Non-Motor Dysfunction (Second Edition). Humana Press/Springer:New York. pp. 155-171, 2013.
59. Pfeiffer RF: Catechol-O-Methyltransferase Inhibitors. In: Pahwa R, Lyons K (eds). Handbook of Parkinson’s Disease (Fifth Edition). Taylor & Francis:New York. pp. 448-465, 2013
60. Pfeiffer RF: Neurologic manifestations of malabsorption syndromes. In: Biller J (ed). Neurologic Aspects of Systemic Diseases (Handbook of Clinical Neurology). Elsevier:Amsterdam pp. 621-632, 2014. .
19 RFPfeiffer
61. Pfeiffer RF: Other neurological disorders associated with gastrointestinal disease. In: Aminoff MJ, Josephson SJ (eds). Aminoff’s Neurology and General Medicine, Fifth Edition. Elsevier:Amsterdam pp. 237-253, 2014
62. Pfeiffer RF: The Phenotypic Spectrum of Parkinson’s Disease. In: LeDoux M (ed.). Animal Models of Movement Disorders, Second Edition. Elsevier/Academic Press:San Diego (in press).
63. Lewitt P, Pfeiffer RF: Neurologic Aspects of Wilson’s Disease: Clinical Manifestations and Treatment Considerations. In: Jankovic J, Tolosa E (eds). Parkinson’s Disease & Movement Disorders (Sixth Edition).Lippincott Williams & Wilkins:Philadelphia. (in press).
64. Pfeiffer RF. Neurogenic Dysphagia. In: Daroff RB, Jankovic J, Mazziotta JC, Pomeroy SL (eds): Bradley’s Neurology in Clinical Practice (Seventh Edition). Elsevier/Saunders:Philadelphia. (in press).
65. Pfeiffer RF: Neurogastroenterology. In: Nabel EG (ed. in chief). Scientific American Medicine. Decker:Hamilton, Ontario. (in press).
Articles Published:
1. Pfeiffer RF, Ebadi MS: On the mechanisms of the nullification of CNS effects of levodopa by pyridoxine in parkinsonian patients. Journal of Neurochemistry 19:2175-2181, 1972.
2. Pfeiffer RF: Comments on the adverse effect of concurrent pyridoxine administration on the efficacy of L-dopa in treating parkinsonism. Nebraska Medical Journal 47:366-374, 1972.
3. Guidotti A, Zivkovic B, Pfeiffer RF, Costa E: Involvement of 3'5' cyclic adenosine monophosphate in the increase of tyrosine hydroxylase activity elicited by cold exposure. Naunyn-Schmiedeberg's Archives Pharmacology 278:195-206, 1973.
4. Teychenne PF, Kartzinel R, Perlow M, Pfeiffer RF, Calne DB: Clinical studies with bromocriptine in idiopathic parkinsonism. Transactions of the American Neurologic Association 101:302-304, 1976.
5. Silbergeld EK, Pfeiffer RF: Differential effects of three dopamine agonists: Apomorphine, bromocriptine and lergotrile. Journal of Neurochemistry 28:1323-1326, 1977.
6. Teychenne PF, Pfeiffer RF, Bern S, Calne DB: Experiences with a new ergoline (CF25-397) in parkinsonism. Neurology 27:1140-1143, 1977.
7. Teychenne PF, Pfeiffer RF, Bern SM, McInturff D, Calne DB: Comparison between lergotrile and bromocriptine in parkinsonism. Annals of Neurology 3:319-324, 1978.
8. Neophytides AN, Teychenne PF, Pfeiffer RF, Calne DB: Sodium valproate in the treatment of cerebellar disorders. Canadian Journal of Neurological Sciences 6:455-457, 1979.
9. Pfeiffer RF: Drugs for pain in the elderly. Geriatrics 37:67-76, 1982.
10. Streib EW, Sun SF, Pfeiffer RF: Toe extensor weakness resulting from trivial athletic trauma. American Journal of Sports Medicine 10(5):311-314, 1982.
20 RFPfeiffer
11. Pfeiffer RF: Neurologic drug toxicity in the emergency room. Seminars in Neurology 3:68-75, 1983.
12. Ebadi M, Pfeiffer RF: Zinc in neurological disorders and in experimentally-induced epileptic seizures. Neurology and Neurobiology 11B:307-324, 1984.
13. Pfeiffer RF, Wilken K, Glaeske C, Lorenzo AP: Low dose bromocriptine therapy in Parkinson's disease. Archives of Neurology 42:586-588, 1985.
14. Pfeiffer RF, Wilken K, Glaeske C: Mesulergine (CU32-085) in the treatment of Parkinson's disease. Annals of Neurology 17:334-336, 1985.
15. Schneider MB, Murrin LC, Pfeiffer RF, Deupree J: Dopamine receptors: Effects of chronic L- dopa and bromocriptine treatment in an animal model of Parkinson's disease. Clinical Neuropharmacology 7:247-257, 1985.
16. Pfeiffer RF: The pharmacology of mesulergine. Clinical Neuropharmacology 8:64-72, 1985.
17. Cronin SM, Pfeiffer RF: Drug therapy for Parkinson's disease. Family Practice Recertification 7:93-108, 1985.
18. Erlander MG, Parliman JA, Draper DD, Christian LL, Murrin LC, Pfeiffer RF, and Beitz DC: Effects of L-dopa supplementation on concentrations of brain catechols, dopamine receptor binding and the incidence of pale, soft and exudative meat in stress-susceptible pigs. Journal of Animal Science 61:914-912, 1985.
19. Kenny AM, Schneider MB, Baden DR, Pfeiffer RF, Murrin LC: Bromocriptine holiday: Effects on dopamine receptors and turning behavior in rats. Neurology 36:400-404, 1986.
20. Kenny AM, Murrin LC, Pfeiffer RF: Drug holiday in Parkinson's disease. Nebraska Medical Journal 72:149-153, 1987.
21. Sullivan JM, Wszolek ZK, Lund G, Pfeiffer RF: Clinical diagnostic imaging, magnetic resonance imaging in thoracic outlet syndrome. Nebraska Medical Journal 73:70-72, 1988.
22. Sullivan JM, Wszolek ZK, Lund G, Pfeiffer RF: Thoracic Outlet Syndrome. Neurosurgery 23: 271-272, 1988.
23. Wszolek ZK, Monsour H, Smith P, Pfeiffer RF: Cryptococcal meningoencephalitis with parkinsonian features. Movement Disorders 3:271-273, 1988.
24. Scholer SG, Pfeiffer RF: Progressive supranuclear palsy: A case report. Nebraska Medical Journal 73:263-269, 1988.
25. Ebadi M, Hexum TD, Pfeiffer RF, Govitrapong P: Pineal and retinal peptides and their receptors. Pineal Research Reviews 7:1-156, 1989.
26. Govitrapong P, Hama Y, Pfeiffer RF, Ebadi M: Status of dopamine in bovine pineal glands and the stimulation of N-acetyl-transferase activity by D2-dopaminergic receptor agonists in the rat pineal glands in culture. Journal of Pineal Research 6:17-31, 1989.
27. Pfeiffer RF, Herrera LH, Glaeske CS, Hofman RE: CQP 201-403 in Parkinson's disease. An open-label pilot study. Movement Disorders 4:278-281, 1989.
21 RFPfeiffer
28. Parkinson Study Group: DATATOP: A multi-center controlled clinical trial in early Parkinson's disease. Archives of Neurology 46:1052-1060, 1989.
29. Pfeiffer RF, Sucha EL: "On-off" - induced lethal hyperthermia. Movement Disorders 4:338-341, 1989.
30. Parkinson Study Group: Effect of deprenyl on the progression of disability in early Parkinson's disease. The New England Journal of Medicine 321:1364-1371, 1989.
31. Wszolek ZK, McComb RD, Pfeiffer RF, Steg RE, Wood RP, Shaw BW Jr, Markin RS: Pontine and extrapontine myelinolysis following liver transplantation: Relationship to serum sodium. Transplantation 48:1006-1012, 1989.
32. McComb RD, Pfeiffer RF, Casey JH, Wolcott G, Till DJ: Pontine and extrapontine myelinolysis associated with hypernatremia and hyperglycemia. Clinical Neuropathology 8:284-288, 1989.
33. Shoulson I, and the Parkinson Study Group: Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Acta Neurologica Scandinavica 80(Suppl. 126):171-175, 1989.
34. Pfeiffer RF: Bromocriptine-induced hypothermia. Neurology 40:383, 1990.
35. Pfeiffer RF, McComb RD: Dentatorubro-pallidoluysian atrophy of the myoclonus epilepsy type with posterior column degeneration. Movement Disorders 5:134-138, 1990.
36. Ebadi M, Murrin LC, Pfeiffer RF: Hippocampal zinc thionein and pyridoxal phosphate modulate synaptic functions. Annals of the New York Academy of Science 585:189-201, 1990.
37. Ebadi M, Pfeiffer RF, Murrin LC: Pathogenesis and treatment of neuroleptic malignant syndrome. General Pharmacology, 2:367-386, 1990.
38. Pfeiffer RF, Kang J, Graber B, Hofman R, Wilson J: Clozapine for psychosis in Parkinson's disease. Movement Disorders 5:239-242, 1990.
39. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I, Stern M, Tanner C, Weiner W, and the Parkinson Study Group: Variable clinical expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. Neurology 40:1529-1534, 1990.
40. Gasecki AP, Pfeiffer RF: Cysticercosis of the brain in the USA. Neurologia i Neurochirurgia Polska 24: 111-112, 1990.
41. Pfeiffer RF, Wilken KE, Glaeske CS, Hofman R: Sinemet CR in Parkinson's disease. Nebraska Medical Journal 76:8-10, 1991.
42. Pfeiffer RF, Hofman R: CQA 206-291 in Parkinson's disease. Clinical Neuropharmacology 14:170-178, 1991.
43. Edwards LL, Pfeiffer RF, Quigley E, Hofman R, Balluff M: Gastrointestinal symptoms in Parkinson's disease. Movement Disorders 6:151-156, 1991.
44. Wszolek ZK, Aksamit AJ, Ellingson RJ, Sharbrough FW, Westmoreland BF, Pfeiffer RF, Steg RE, de Groen PC: Epileptiform electroencephalographic abnormalities in liver transplant recipients. Annals of Neurology 30:37-41, 1991.
22 RFPfeiffer
45. Parkinson Study Group: DATATOP and clinical neuromythology IX. Neurology 41:771-773, 1991.
46. LeWitt P, and the Parkinson Study Group: Deprenyl's effect at slowing progression of parkinsonian disability: The DATATOP Study. Acta Neurologica Scandinavica 84: Suppl 136: 70-86, 1991.
47. Ebadi M, Pfeiffer RF, Murrin LC, Shiraga H: Metallothionein and oxidation reactions in Parkinson's disease. Proceedings of the Western Pharmacology Society 34:285-290, 1991.
48. Pfeiffer RF: Optimalization of levodopa therapy. Neurology 42 (Suppl. 1):39-43, 1992.
49. Edwards LL, Quigley EMM, Pfeiffer RF: Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 42:726-731, 1992.
50. Wszolek ZK, Pfeiffer RF, Bhatt MH, Schelper RL, Cordes M, Snow BJ, Rodnitzky RL, Wolters ECh, Arwert F, Calne DB: Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration. Annals of Neurology 32:312-320, 1992.
51. Ebadi M, Pfeiffer RF, Murrin LC: Neuroleptic-induced movement disorders. Current Aspects of Neurosciences 4:159-203, 1992.
52. Shoulson I, and the Parkinson Study Group: An interim report of the effect of selegiline (L- deprenyl) on the progression of disability in early Parkinson's disease. European Neurology 32(suppl 1):46-53, 1992.
53. Ebadi M, Pfeiffer RF, Huff A: Differential stimulation of hepatic and brain metallothioneins by ethanol. Neurochemistry International 21:555-562, 1992.
54. Wszolek ZK, Pfeiffer RF: Genetic considerations in movement disorders. Current Opinion Neurology & Neurosurgery 5:324-330, 1992.
55. Cordes M, Wszolek Z, Rodnitzky RL, Pfeiffer RF, Calne DB: MRI studies in rapidly progressive autosomal-dominant parkinsonism and dementia with pallido-ponto-nigral degeneration. Neurodegeneration 1:217-224, 1992.
56. LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M, Srivastava DK, Oakes D, and the Parkinson Study Group: Markers of dopamine metabolism in Parkinson's disease. Neurology 42:2111-2117, 1992.
57. Edwards L, Quigley EMM, Harned RK, Hofman R, Pfeiffer RF: Gastrointestinal symptoms in Parkinson's disease: 18-Month Follow-Up Study. Movement Disorders 8:83-86, 1993.
58. Parkinson Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. New England Journal of Medicine 328:176-183, 1993.
59. Hao R, Pfeiffer R, Ebadi M: Purification and characterization of metallothionein and its activation of pyridoxal phosphokinase in trout brain. Comparative Biochemistry & Physiology 104B:293-298, 1993.
60. Ebadi M, Samejima M, Pfeiffer RF: Pineal gland in synchronizing and refining physiological events. News in Physiological Studies, 8:30-34, 1993.
23 RFPfeiffer
61. Edwards LL, Quigley EMM, Harned RK, Hofman R, Pfeiffer RF: Defecatory function in Parkinson's disease: Response to apomorphine. Annals of Neurology, 33:490-493, 1993.
62. Wszolek ZK, Cordes M, Calne DB, Muenter MD, Cordes I, Pfeiffer RF: Hereditary Parkinson's disease: report on three families with autosomal-dominant inheritance pattern. Nervenärzt (German) 64:331-335, 1993.
63. Cordes M, Wszolek ZK, Pfeiffer RF, Calne DB: Examination of the presynaptic dopaminergic system using positron emission tomography in a family with autosomal dominant parkinsonism and dementia due to pallido-ponto-nigral degeneration. Radiologia Diagnostica. 34:141-145. 1993.
64. Shimoda K, Shen GH, Pfeiffer RF, McComb RD, Yang HYT: Antiserum against neuropeptide Y enhances the nicotine-mediated release of catecholamines from cultured rat adrenal chromaffin cells. Neurochemistry International 23:1:71-77, 1993.
65. Shiraga H, Pfeiffer RF, Ebadi M: The effects of 6-hydroxydopamine and oxidative stress on the level of brain metallothionein. Neurochemistry International 23:6:561-566, 1993.
66. Shults CW, and the Parkinson Study Group. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Acta Neurologica Scandinavica Supplement 87:36-42, 1993.
67. Yamada T, McGeer EG, Schelper RL, Wszolek ZK, McGeer PL, Pfeiffer RF, Rodnitzky RL: Histological and biochemical pathology in a family with autosomal dominant Parkinsonism and dementia. Neurology, Psychiatry and Brain Research 2:26-35, 1993.
68. Edwards L, Quigley EMM, Harned RK, Hofman R, Pfeiffer RF: Characterization of swallowing and defecation in Parkinson's disease. American Journal of Gastroenterology 89:15-25, 1994.
69. Samejima M, Happe HK, Murrin LC, Pfeiffer RF, Ebadi M: Distribution of cholinergic and dopaminergic receptors in rainbow trout pineal gland. Journal of Pineal Research 16:37-43, 1994.
70. Hao R, Cerutis R, Blaxall H, Rodriquez-Sierra JF, Pfeiffer RF, Ebadi M: Localization of metallothionein I messenger RNA in rat brain by in situ by hybridization. Neurochemical Research 19:761-767, 1994.
71. Shiraga H, Stallwood D, Ebadi M, Pfeiffer R, Landers D, Paul S: Inhibition of calmodulin- dependent myosin light chain kinase by growth hormone releasing factor and vasoactive intestinal peptide. Biochemical Journal 300: 901-905, 1994
72 Ashraf W, Pfeiffer RF, Quigley EMM: Anorectal manometry in the assessment of anorectal function in Parkinson's disease: a comparison with chronic idiopathic constipation. Movement Disorders 9: 655-663, 1994.
73. Hiramatsu M, Kohno M, Mori A, Shiraga H, Pfeiffer RF, Ebadi M: An ESR study of 6- hydroxydopamine: Generated hydroxy radicals and superoxide anions in brain. Neurosciences 20: 129-138, 1994.
74. Gasser T, Wszolek ZK, Trofalter J, Ozelius L, Uitti RJ, Lee CS, Gusella J, Pfeiffer RF, Calne DB, Breakefield XO: Genetic linkage studies in autosomal dominant parkinsonism: Evaluation of seven candidate genes. Annals of Neurology 36: 387-396, 1994.
24 RFPfeiffer
75. Shiraga H, Pfeiffer R, Ebadi M: Differential induction of metallothionein by dopamine in neuroblastoma IMR 32 and Chang liver cells in culture. Biological Trace Element Research Biochem Journal 20:901-905, 1994
76. Kieburtz K, McDermott M, Como P, Growdon J, Brady J, Carter J, Huber S, Kanigan B, Landow E, Rudolph A, Saint-Cyr J, Stern Y, Tennis M, Thalen J, Shoulson I, and the Parkinson Study Group: The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Neurology 44:1756-1759, 1994.
77. Byrne KG, Pfeiffer R, Quigley EMM: Gastrointestinal dysfunction in Parkinson’s disease: A report of clinical experience at a single center. Journal of Clinical Gastroenterology 19: 11-16, 1994.
78. Quigley EMM, Pfeiffer RF: Gastrointestinal dysfunction in neurological disease: a report of an interdisciplinary international symposium. Neurogastroenterology and Motility 6:55-57, 1994.
79. Hao R, Norgren RB Jr, Lau YS, Pfeiffer RF: Cerebrospinal fluid of Parkinson's disease patients inhibits the growth and function of dopaminergic neurons in culture. Neurology 45:138-142, 1995.
80. Wszolek ZK, Pfeiffer B, Fulgham JR, Parisi JE, Thompson BM, Uitti RJ, Calne DB, Pfeiffer RF: Western Nebraska family (Family D) with autosomal dominant Parkinson's disease. Neurology 45:502-505, 1995.
81. Ashraf W, Wszolek ZK, Pfeiffer RF, Quigley EMM, Normand M, Srb F, Maurer K: Anorectal function in fluctuating (on-off) Parkinson’s disease: Evaluation by combined anorectal manometry and electromyography. Movement Disorders 10: 650-657, 1995.
82. Markopoulou K, Wszolek ZK, Pfeiffer RF: A Greek-American family with autosomal dominant levodopa-responsive parkinsonism. Annals of Neurology 38:373-378, 1995.
83. Singaram C, Ashraf W, Torbey C, Sengupta A, Pfeiffer R, Quigley EMM: Dopaminergic defect of enteric nervous system in Parkinson’s disease patients with chronic constipation. Lancet 346:861-864, 1995.
84. Hao R, Ebadi M, Pfeiffer RF: Selegiline protects dopaminergic neurons in culture from toxic factor(s) present in the cerebrospinal fluid of patients with Parkinson’s disease. Neuroscience Letters 200:77-80, 1995.
85. Ebadi M, Iverson PL, Hao R, Cerutis DR, Rojas Castenada P, Happe HK, Murrin LC, Pfeiffer RF: Induction and expression of brain metallothionein. Neurochemistry International 27:1-22, 1995.
86. Parkinson Study Group. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson’s disease. Archives of Neurology 52:237-245, 1995.
87. McDermott MP, Jankovic J, Carter J, Fahn S, Gauthier S, Goetz CG, Golbe LI, Koller W, Lang AE, Olanow CW, Shoulson I, Stern MB, Tanner CM, Weiner WJ, and the Parkinson Study Group: Factors predictive of the need for levodopa therapy in early, untreated Parkinson’s disease. Archives of Neurology 52:565-570, 1995.
88. Normand MM, Ashraf W, Quigley EMM, Maurer KB, Edwards L, Pfeiffer RF, Wszolek ZK: Simultaneous electromyography and manometry of the anal sphincters in parkinsonian patients: Technical considerations. Muscle and Nerve 19:110-111, 1996.
25 RFPfeiffer
89. Wijker M, Wszolek ZK, Wolters ECh, Rooimans MA, Pals G, Pfeiffer RF, Lynch T, Rodnitzky RL, Wilhelmsen KC, Arwert F: Localization of the gene for rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration to chromosome 17q21. Human Molecular Genetics 5:151-154, 1996.
90. Born LJ, Harned RH, Rikkers LF, Pfeiffer RF, Quigley EMM: Cricopharyngeal dysfunction in Parkinson’s disease: Role in dysphagia and response to myotomy. Movement Disorders 11:53- 58, 1996.
91. Pfeiffer RF: Amantadine-induced “vocal” myoclonus. Movement Disorders 11:104-106, 1996.
92. Parkinson Study Group: Impact of Deprenyl and Tocopherol Treatment on Parkinson’s Disease in DATATOP Subjects Not Requiring Levodopa. Annals of Neurology 39(1):29-36, 1996.
93. Parkinson Study Group: Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects requiring levodopa. Annals of Neurology 39(1):37-45, 1996.
94. Wszolek ZK, Pfeiffer RF, Denson MA, McComb RD: Danish-American family (Family E) with “Parkinson’s disease”: Pitfalls of genetic studies. Parkinsonism and Related Disorders 2:47-49, 1996.
95. Hutton JT, Koller WC, Ahlskog JE, Pahwa R, Hurtig HI, Stern MB, Hiner BC, Lieberman A, Pfeiffer RF, Rodnitzky RL, Waters CH, Muenter MD, Adler CH, Morris JL: Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson’s disease. Neurology 46:1062-1065, 1996.
96. Antal A, Pfeiffer R, Bodis-Wollner I: Simultaneously evoked primary and cognitive visual evoked potentials distinguish younger and older patients with Parkinson’s disease. Journal of Neural Transmission 103:1053-1067, 1996.
97. Strickland D, Bertoni JM, Pfeiffer RF: Descriptive epidemiology of Parkinson’s disease through proxy measures. Canadian Journal of Neurological Sciences 23:279-284, 1996.
98. Pfeiffer RF: Antiparkinson agents: Drug interactions of clinical significance. Drug Safety 14:343-354, 1996.
99. Rojas P, Cerutis DR, Happe HK, Murrin LC, Hao R, Pfeiffer RF, Ebadi M: 6- hydroxydopamine-mediated induction of the rat hippocampal metallothionein I mRNA. Neurotoxicology 17:323-334, 1996.
100. Pfeiffer RF: Neurologic dysfunction in gastrointestinal disease. Seminars in Neurology 16:217- 226, 1996.
101. Pfeiffer R.F, Bodis-Wollner I: Charles Bonnet syndrome (editorial). Journal of the American Geriatric Society 44:1128, 1996.
102 LeWitt P, Oakes D, Cui L, and the Parkinson Study Group. The need for levodopa as an end point of Parkinson’s disease progression in a clinical trial of selegiline and alpha-tocopherol. Movement Disorders 12:183-189, 1997.
26 RFPfeiffer
103. Lieberman A, Ranhosky A, Kortis D, (for the Pramipexole Study Group): Clinical evaluation of pramipexole in advanced Parkinson’s disease: Results of a double-blind, placebo-controlled, parallel-group study. Neurology 49:162-168, 1997.
104. Widman LP, Burke WJ, Pfeiffer RF, McArthur-Campbell: Use of clozapine to treat levodopa- induced psychosis in Parkinson’s disease: A retrospective review. Journal of Geriatric Psychiatry and Neurology 10:63-66, 1997.
105. Hao R, MacDonald RG, Ebadi M, Schmit JC, Pfeiffer RF: Stable interaction between G-actin and neurofilament light subunit in dopaminergic neurons. Neurochemistry International 31:825- 834, 1997.
106. Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EMM: Constipation in Parkinson’s disease: Objective assessment and response to psyllium. Movement Disorders 12:946-951, 1997.
107. Markopoulou K, Larsen KW, Wszolek EK, Denson M, Lang AE, Pfeiffer RF, Wszolek ZK: Olfactory dysfunction in familial parkinsonism. Neurology 49:1262-1267, 1997.
108. Denson MA, Wszolek ZK, Pfeiffer RF, Wszolek EK, Paschall TM, McComb RD: Familial parkinsonism, dementia, and Lewy body disease: Study of family G. Annals of Neurology 42:638-643, 1997.
109. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez- Ramos J, O'Brien CF, for the Ropinirole Study Group: Ropinirole for the treatment of Parkinson's disease. Neurology 49:393-399, 1997.
110. Wszolek ZK, Vieregge P, Uitti RJ, Gasser T, Yasuhara O, McGeer P, Berry K, Calne DB, Vingerhoets FJG, Klein C, Pfeiffer RF: German-Canadian family (Family A) with parkinsonism, amyotrophy, and dementia: Longitudinal observations. Parkinsonism and Related Disorders 3:125-139, 1997.
111. Richard IH, Kurlan R, and the Parkinson Study Group: A survey of antidepressant drug use in Parkinson’s disease. Neurology 49:1168-1170, 1997.
112. Parkinson Study Group (Kieburtz K, corresponding author): The COMT inhibitor entacapone increases on time in levodopa treated Parkinson’s disease patients with motor fluctuations. Annals of Neurology 42:747-755, 1997.
113. Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C, and the Parkinson Study Group: Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology 48:1070-1077, 1997.
114. Vatassery GT, Fahn S, Kuskowski MA, and the Parkinson Study Group: Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Neurology 50:1900-1902, 1998.
115. Growdon JH, Kieburtz K, McDermott MP, Panisset M, Friedman JH, and the Parkinson Study Group: Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Neurology 50:1327-1331, 1998.
116. Lau Y-S, Hao R, Fung YK, Fu L-S, Bishop JF, Pfeiffer RF, Mouradian MM: Modulation of nigrostriatal dopaminergic transmission by an antisense oligodeoxynucleotide against brain- derived neurotrophic factors. Neurochemical Research 23:525-532, 1998.
27 RFPfeiffer
117. Ebadi M, Ramana Kumari MV, Hiramatsu M, Hao R, Pfeiffer RF, Rojas P: Metallothionein, neurotrophins and selegiline in providing neuroprotection in Parkinson’s disease . Restorative Neurology and Neuroscience 12:1-9, 1998.
118. LeDoux MS, McGill LJ, Pulsinelli WA, Pfeiffer RF, Deuschl G, Siderowf A, Kurlan R, Sethi K: Severe bilateral kinetic tremor in a liver transplant recipient on cyclosporine. Movement Disorders 13:589-596, 1998.
119. Parkinson Study Group: Mortality in DATATOP: A multicenter trial in early Parkinson’s disease. Annals of Neurology 43:318-325, 1998.
120. Shoulson I, and the Parkinson Study Group: DATATOP. A decade of neuroprotective inquiry. Annals of Neurology 44 (suppl): S160-S166, 1998.
121. Wengel SP, Burke WJ, Pfeiffer RF, Roccaforte WH, Paige SR: Maintenance electroconvulsive therapy for intractable Parkinson’s disease. American Journal of Geriatric Psychiatry 6:263-269, 1998.
122. Burke WJ, Pfeiffer RF, McComb RD: Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. Journal of Neuropsychiatry and Clinical Neurosciences 10:227-229, 1998.
123. Parkinson Study Group: Low dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. New England Journal of Medicine 340:757-763, 1999.
124. Pfeiffer RF, Quigley EMM: Gastrointestinal motility problems in patients with Parkinson's disease: Effects of antiparkinsonian treatments and guidelines for management. CNS Drugs 11:435-448, 1999.
125. Markopoulou K, Wszolek ZK, Pfeiffer RF, Chase BA: Reduced expression of the G209A alpha- synuclein allele in familial parkinsonism. Annals of Neurology 46:374-381, 1999.
126. Shetty N, Friedman JH, Kieburtz K, Marshall FJ, Oakes D, and the Parkinson Study Group: The placebo response in Parkinson's disease. Clinical Neuropharmacology 22:207-212, 1999.
127. Parkinson Study Group: A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: Design and methods of the CALM-PD study. Clinical Neuropharmacology 23:34-44, 2000.
128. Parkinson Study Group: A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD. Neurology 54:1583-1588, 2000.
129. Pfeiffer RF: Gastrointestinal dysfunction in Parkinson's disease. Clinical Neuroscience 5:136- 146, 1998 (published in 2000).
130. Parkinson Study Group: A randomized controlled trial comparing the agonist pramipexole with levodopa as initial dopaminergic treatment in Parkinson's disease. Journal of the American Medical Association 284:1931-1938, 2000.
131. Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeosis K, and the Parkinson Study Group: Clozapine for the Treatment of drug-induced psychosis in Parkinson’s disease; results of the 12 week open label extension in the PSYCLOPS trial. Movement Disorders 16: 135-139, 2001.
28 RFPfeiffer
132. Wszolek ZK, Kardon RH, Wolters EC, Pfeiffer RF: Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17): The PPND family. A longitudinal videotape demonstration. Movement Disorders 16: 756-760, 2001.
133. Pfeiffer RF: Brain meets gut: gastroesophageal reflux (editorial). Clinical Autonomic Research 11:3-4, 2001
134. Wszolek ZK, Gwinn-Hardy K, Wszolek EK, Muenter MD, Pfeiffer RF, Rodnitzky RL, Uitti RJ, McComb RD, Gasser T, Dickson DW: Neuropathology of two members of a German-American kindred (Family C) with late onset parkinsonism. Acta Neuropathologica 103:344-350, 2002.
135. Parkinson Study Group: Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson’s disease progression. Journal of the American Medical Association 287: 1653-1661, 2002.
136. Siddiqui MF, Rast S, Lynn MJ, Auchus AP, Pfeiffer RF: Autonomic dysfunction in Parkinson’s disease: A comprehensive symptom survey. Parkinsonism and Related Disorders 8:277-284, 2002.
137. Shoulson I, Oakes D, Fahn S, Lang A, Langston WJ, LeWitt P, Olanow W, Penney JB, Tanner C, Kieburtz K, Rudolph A, and the Parkinson Study Group: Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: A randomized, placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Annals of Neurology 51:604-612, 2002.
138. Huang Z, Jacewicz M, Pfeiffer RF: Anticardiolipin antibody in vascular parkinsonism. Movement Disorders 17:992-997, 2002.
139. Pfeiffer RF: Potential of transdermal drug delivery in Parkinson’s disease. Drugs & Aging 19:561-570, 2002.
140. Nichols WC, Pankratz N, Uniacke SK, Pauciulo MW, Halter C, Rudolph A, Conneally PM, Foroud T, and the Parkinson Study Group: Linkage stratification and mutation analysis at the parkin locus identifies mutation positive Parkinson’s disease families. Journal of Medical Genetics 39:489-492, 2002.
141. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T, and the Parkinson Study Group: Genome screen to identify susceptibility genes for Parkinson’s disease in a sample without parkin mutations. American Journal of Human Genetics 71:124-135, 2002.
142. Reider CR, Halter CA, Castelluccio PF, Oakes D, Nichols WC, Foroud T, and the Parkinson Study Group: Reliability of reported age at onset for Parkinson’s disease. Movement Disorders 18:275-279, 2003.
143. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T, and the Parkinson Study Group: Significant linkage of Parkinson disease to chromosome 2q36-37. American Journal of Human Genetics 72:1053-1057, 2003.
144. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, Shults C, Marder K, Conneally PM, Nichols WC, and the Parkinson Study Group: Heterozygosity for a mutation in the parkin gene leads to a later onset Parkinson disease. Neurology 60:796- 801, 2003.
29 RFPfeiffer
145. Pfeiffer RF: Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurology 2:107- 116, 2003.
146. Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A, Shults CW, Conneally PM, Foroud T, Parkinson Study Group: Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Human Molecular Genetics 12:2599-2608, 2003
147. Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R, and the Parkinson Study Group: Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology 60:1756-1761, 2003.
148. Welsh, M., McDermott, M.P., Holloway, R.G., Plumb, S., Pfeiffer, R., Hubble, J., and the Parkinson Study Group. Development and Testing of the Parkinson's Disease Quality of Life Scale. Movement Disorders 18:637-645, 2003.
149. Marras C, Lang A, Krahn M, Tomlinson G, Naglie G, and the Parkinson Study Group: Quality of life in early Parkinson’s disease: impact of dyskinesias and motor fluctuations. Movement Disorders 19:22-28, 2004.
150. Parkinson Study Group: The safety and tolerability of a mixed lineage kinase inhibitor (CEP- 1347) in PD. Neurology 62:330-332, 2004.
151. Noyes K, Dick A, Holloway RG, and the Parkinson Study Group: Pramipexole vs. levodopa as initial treatment for Parkinson’s disease. A randomized clinical-economic trial. Medical Decision Making 24:472-485, 2004.
152. Zimprich A, Muller-Myhsok B, Farrer M, Leitner P, Sharma M, Hulihan M, Lockhart P, Strongosky A, Kachergus J, Calne DB, Stoessl J, Uitti RJ, Pfeiffer RF, Trenkwalder C, Homann N, Ott E, Wenzel K, Asmus F, Hardy J, Wszolek Z, Gasser T: The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease- containing interval. American Journal of Human Genetics 74:11-19, 2004.
153. Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, Strongosky AA, Zimprich A, Müller-Myhsok B, Farrer MJ, Gasser T, Calne DB, Dickson DW: Autosomal dominant parkinsonism associated with variable synuclein and tau pathology: Update on studies of Family D (Western Nebraska). Neurology 62:1619-1622, 2004.
154. Pankratz N, Uniacke SK, Halter CA, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC; Parkinson Study Group: Genes influencing Parkinson disease onset: replication of PARK3 and identification of novel loci. Neurology 62:1616-1618, 2004.
155. Nichols WC, Uniacke SK, Pankratz N, Reed T, Simon DK, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T; Parkinson Study Group: Evaluation of the role of Nurr1 in a large sample of familial Parkinson’s disease. Movement Disorders 19:649-655, 2004.
156. Parkinson Study Group: Pramipexole vs. levodopa as initial treatment of Parkinson’s disease. Archives of Neurology 61:1044-1053, 2004.
157. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Müller- Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T: Mutations in LRRK2
30 RFPfeiffer
cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601-607, 2004.
158. Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, Lang AE, and the Parkinson Study Group: Survival in Parkinson disease. Thirteen-year follow-up of the DATATOP cohort. Neurology 64:87-93, 2005.
159. Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C, Jain S, Halter C, Michaels VE, Reed T, Rudolph A, Shults CW, Singleton A, Foroud T; Parkinson Study Group-PROGENI Investigators: Genetic screening for a single common LRRK2 mutation in familial Parkinson’s disease. Lancet 365:410-412, 2005.
160. Nausieda P, Pfeiffer RF, Tagliati M, Kastenholz KV, DeRoche C, Slevin JT: A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson’s disease. Clinical Therapeutics 27:58-63, 2005
161. Pfeiffer RF: Neurological dysfunction in gastrointestinal diseases. Continuum 11:59-84, 2005.
162. Pfeiffer RF: A promising new technology for Parkinson’s disease. Neurology 65(Suppl 1):S6- S10, 2005.
163. Noyes K, Dick AW, Holloway RG, and the Parkinson Study Group. Pramipexole and levodopa in early Parkinson’s disease: dynamic changes in cost effectiveness. Pharmacoeconomics 23:1257-1270, 2005.
164. Pankratz N, Byder L, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC and the Parkinson Study Group-PROGENI Investigators: Presence of an APOE4 allele results in significantly earlier onset of Parkinson disease and a higher risk of PD with dementia. Movement Disorders 21:45-49, 2006.
165. Parkinson Study Group: A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Archives of Neurology 63:210-216, 2006.
166. Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T, Nichols WC, and the Parkinson Study Group – PROGENI Investigators: Mutations in LRRK2 other than G2019S are rare in a North American-based sample of familial Parkinson’s disease. Movement Disorders 21:2257-2260, 2006.
167. Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Wojcieszek J, Rudolph A, Shults CW, Foroud T, Nichols WC, Parkinson Study Group – PROGENI Investigators: Mutations in DJ-1 are rare in familial Parkinson disease. Neuroscience Letters 408:209-213, 2006.
168. Nichols WC, Marek DK, Pauciulo MW, Pankratz N, Halter CA, Rudolph A, Shults CW, Wojcieszek J, Foroud T, and the Parkinson Study Group – PROGENI Investigators: R1514Q substitution in Lrrk2 is not a pathogenic Parkinson’s disease mutation. Movement Disorders 22:254-257, 2007.
169. Pfeiffer RF, Gutmann L, Hull KL Jr, Bottini PB, Sherry JH, and the APO302 Study Investigators: Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism and Related Disorders 13:93-100, 2007.
170. Pfeiffer RF: Wilson’s disease. Seminars in Neurology 27:123-132, 2007.
31 RFPfeiffer
171. Parkinson Study Group: Pramipexole in levodopa treated Parkinson’s disease patients of African, Asian and Hispanic heritage. Clinical Neuropharmacology 30:72-85, 2007.
172. Pfeiffer RF: Transdermal drug delivery in Parkinson’s disease. Aging Health 3:471-482, 2007.
173. Parkinson Study Group PRECEPT Investigators: The mixed lineage kinase inhibitor CEP- 1347 fails to delay disability in early Parkinson disease. Neurology 69:1480-1490, 2007.
174. Pfeiffer RF: Non-motor parkinsonism. Parkinsonism and Related Disorders 13:S211-S220, 2007.
175. Nichols WC, Elsaesser VE, Pankratz N, Pauciulo MW, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T, for the Parkinson Study Group-PROGENI Investigators: LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. Neurology 69:1737- 1744, 2007.
176. Constantinescu R, Romer M, McDermott M, Kamp C, Kieburtz K, and the Parkinson Study Group-CALM-PD Investigators: Impact of pramipexole on the onset of levodopa related dyskinesias. Movement Disorders 22:1317-1319, 2007.
177. Biglan KM, Holloway RG, McDermott MP, Richard IH, and the Parkinson Study Group- CALM-PD Investigators: Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 69:187-195, 2007.
178. Hauser RA, McDermott MP, Messing S, and the Parkinson Study Group-CALM-PD Investigators: Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Archives of Neurology 63:1756-1760, 2007.
179. Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Lang AE, and the Parkinson Study Group DATATOP Investigators: Predictors of deterioration in health-related quality of life in Parkinson’s disease: results from the DATATOP trial. Movement Disorders 23:653-659, 2008.
180. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, and the Parkinson Study Group PRECEPT Investigators: Serum urate as a predictor of clinical and radiographic progression in Parkinson’s disease. Archives of Neurology 65:716-723, 2008.
181. Bloomer RJ, Schilling BK, Karlage RE, LeDoux MS, Pfeiffer, RF, Callegari J: Effect of resistance training on blood oxidative stress in Parkinson’s disease. Medicine & Science in Sports & Exercise 40:1385-1389, 2008
182. Beverly D, Cannito MP, Suiter DM, Chorna L, Wolf T, Watkins J, Pfeiffer R: Formant steadiness: treatment related changes in speakers with hypokinetic dysarthria. Journal of Medical Speech-Language Pathology December 2008.
183. Pankratz N, Marder KS, Halter CA, Rudolph A, Shults CW, Nichols WC, Foroud T, for the Parkinson Study Group – PROGENI investigators: Clinical correlates of depressive symptoms in familial Parkinson’s disease. Movement Disorders 23:2216-2223, 2008.
184. Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T, for the Parkinson Study Group – PROGENI Investigators: Mutations in GBA are associated with familial Parkinson disease susceptibility and age of onset. Neurology 72:310-316, 2009.
32 RFPfeiffer
185. Parkinson Study Group CALM Cohort Investigators: Long-term effect of initiating pramipexole vs. levodopa in early Parkinson disease. Archives of Neurology 66:563-570, 2009.
186. Golub Y, Berg D, Calne DB, Pfeiffer RF, Uitti RJ, Stoessl AJ, Wszolek ZK, Farrer MJ, Mueller JC, Gasser T, Fuchs J: Genetic factors influencing age at onset in LRRK2 linked Parkinson disease. Parkinsonism and Related Disorders. 15:539-541, 2009
187. Nichols WC, Kissell DK, Pankratz N, Pauciulo MW, Essaesser VE, Clark KA, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T, For the Parkinson Study Group-PROGENI Investigators: Variation in GIGYF2 is not associated with Parkinson disease. Neurology. 72:1886-1892, 2009.
188. Pankratz N, Nichols WC, Elsaesser VE, Pauciulo MW, Marek DK, Halter CA, Wojcieszek J, Rudolph A, Pfeiffer RF, Foroud T, for the Parkinson Study Group-PROGENI Investigators: Alpha synuclein and familial Parkinson’s disease. Movement Disorders. 24:1125-1131, 2009.
189. Xiao J, Bastian RW, Perlmutter JS, Racette BA, Tabbal SD, Karimi M, Paniello RC, Blitzer A, Batish SD, Wszolek ZK, Uitti RJ, Hedera P, Simon DK, Tarsy D, Truong DD, Frei KP, Pfeiffer RF, Gong S, Zhao Y, LeDoux MS: High-throughput mutational analysis of TOR1A in primary dystonia. BMC Medical Genetics. 10:24, 2009.
190. Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Marder KS, Foroud T, Nichols WC, for the Parkinson Study Group-PROGENI Investigators: Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology. 73:279-286, 2009.
191. Pankratz N, Wilk JB, Latourelle J, DeStefano AL, Halter C, Pugh EW, Doheny KF, Gusella JF, Nichols WC, Foroud T, Myers RH, and the PSG-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories: Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Human Genetics 124:593-605, 2009.
192. Pfeiffer RF: Nonmotor symptoms in Parkinson disease: the PRIAMO study. Nature Reviews Neurology [News and Views] 5:531-532, 2009.
193. Pfeiffer RF: Neuroinflammation and Parkinson disease. The silent battleground. Neurology [Editorial] 73:1434-1435, 2009.
194. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA, for the Parkinson Study Group DATATOP Investigators: Urate as a predictor of the rate of clinical decline in Parkinson disease. Archives of Neurology 66:E1-E9, 2009.
195. Schilling BK, Karlage RE, LeDoux MS, Pfeiffer RF, Weiss LW, Falvo MJ: Impaired leg extensor strength in individuals with Parkinson disease and relatedness to functional mobility. Parkinsonism and Related Disorders 15:776-780, 2009.
196. Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S, Ross BM, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Caccappolo E, Ottman R, Clark LN, Marder K:
33 RFPfeiffer
Motor phenotype of LRRK2 G2019S carriers in early onset Parkinson disease. Archives of Neurology 66:1517-1522, 2009.
197. Latourelle JC, Pankratz N, Dumitriu A, Wilk JB, Goldwurm S, Pezzoli G, Mariani CB, DeStefano AL, Halter C, Gusella JF, Nichols WC, Myers RH, Foroud T, PROGENI Investigators, Coordinators and Molecular Genetic Laboratories; GenePD Investigators, Coordinators and Molecular Genetic Laboratories: Genomewide association study for onset age in Parkinson disease. BMC Medical Genetics 10:98, 2009.
198. Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I, Parkinson Study Group DATATOP and PRECEPT Investigators: A comparison of treatment thresholds in two large Parkinson’s disease clinical trial cohorts. Movement Disorders 24:2370- 2378, 2009.
199. Ravina B, Tanner C, DiEuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I, and the Parkinson Study Group LABS-PD Investigators: A longitudinal program for biomarker development in Parkinson’s disease: a feasibility study. Movement Disorders 24:2081-2090, 2009.
200. Biglan K, Parkinson Study Group CALM Cohort Investigators: Long-term effect of initiating pramipexole vs. levodopa in early Parkinson disease. Archives of Neurology 66:563- 570, 2009.
201. Uc EY, McDermott MP, Marder KM, Anderson SW, Litvan I, Como PG, Auinger P, Chou KL, Growdon JC, Parkinson Study Group DATATOP Investigators: Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology 73:1469- 1477, 2009.
202. Pfeiffer RF: Neurologic presentations of gastrointestinal disease. Neurology Clinics 28:75-87, 2010.
203. Xiao J, Zhao Y, Bastian RW, Perlmutter JS, Racette BA, Tabbal SD, Karimi M, Paniello R, Wszolek ZK, Uitti RJ, Van Gerpen JA, Simon DK, Tarsy D, Hedera P, Truong DD, Frei KP, Batish SD, Blitzer A, Pfeiffer RF, Gong S, LeDoux MS: Novel THAP1 sequence variants in primary dystonia. Neurology 74:229-238, 2010.
204. Pfeiffer RF: Gastrointestinal, urological, and sexual dysfunction in Parkinson’s disease. Movement Disorders 25(Suppl 1):S94-S97, 2010.
205. Simon DK, Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Nichols WC, Foroud T, Parkinson Study Group-PROGENI Investigators: Maternal inheritance and mitochondrial DNA variants in familial Parkinson’s disease. BMC Medical Genetics 11:53 (9 pages), 2010.
206. Pfeiffer RF: Parkinson disease: calcium channel blockers and Parkinson disease. Nature Reviews Neurology [News and Views] 6:188-189, 2010
207. Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Clark LN, Marder KS, Caccappolo E: Self report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2 and GBA carriers with early onset Parkinson’s disease. Journal of Clinical and Experimental Neuropsychology 32:775-779, 2010.
34 RFPfeiffer
208. Marder K, Tang M-X, Mejia-Santana H, Rosado L, Louis ED, Comella C, Colcher A, Siderowf A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Ross B, Cote L, Frucht S, Ford B, Alcalay RN, Rezak M, Novak K, Friedman J, Pfeiffer R, Marsh L, Hiner B, Neils G, Verbitsky M, Kisselev S, Caccappolo E, Ottman R, Clark LN: Predictors of Parkin mutations in early onset Parkinson disease: the Consortium on Risk for Early-Onset Parkinson Disease study. Archives of Neurology 67:731-738, 2010.
209. Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I and the PSG PRECEPT Investigators: Cancer incidence in a trial of an anti-apoptotic agent for Parkinson’s disease. Movement Disorders 25:1801-1808, 2010.
210. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang M-X, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Marder K, Clark LN: Frequency of known mutations in early onset PD. Implication for genetic counseling: the Consortium on Risk for Early Onset Parkinson Disease Study. Archives of Neurology 67:1116- 1122, 2010.
211. Schilling BK, Pfeiffer RF, LeDoux MS, Karlage RE, Bloomer RJ, Falvo MJ: Effects of moderate volume, high-load lower-body resistance training on strength and function in persons with Parkinson disease: a pilot study. Parkinson’s Disease doi:10.4061/2010/824734.
212. Alcalay RN, Siderowf A, Ottman R, Caccappolo E, Mejia-Santana H, Tang X-M, Rosado L, Louis ED, Ruiz D, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Ross B, Verbitsky M, Kisselev S, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Clark LN, Marder K: Olfaction in parkin heterozygotes and compound heterozygotes: the CORE PD study. Neurology 76:319-326, 2011.
213. Pfeiffer RF: Gastrointestinal dysfunction in Parkinson’s disease. Parkinsonism and Related Disorders 17:10-15, 2011.
214. Caccappolo E, Alcalay RN, Mejia-Sanatan H, Tang M-X, Rakitin B, Rosado L, Louis ED, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner CM, Mickel S, Andrews H, Waters C, Fahn S, Cote LJ, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf AD, Ross BM, Verbitsky M, Kisselev S, Ottman R, Clark LN, Marder K: Neuropsychological profile of parkin mutation carriers with and without Parkinson disease: the CORE-PD study. Journal of the International Neuropsychological Society 17:91-100, 2011.
215. Xiao J, Zhao Y, Bastian RW, Perlmutter JS, Racette BA, Tabbal SD, Karimi M, Paniello RC, Wszolek ZK, Uitti RJ, Van Gerpen JA, Simon DK, Tarsy D, Hedera P, Truong DD, Frei KP, Blitzer A, Rudzińska M, Pfeiffer RF, Le C, LeDoux ML: The c.-237_236GA>TT THAP1 sequence variant does not increase risk for primary dystonia. Movement Disorders 26:549-553, 2011.
216. Srivastava A, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Caccappolo E, Comella C, Colcher A, Siderowf A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Alcalay RN, Ross B, Orbe Reilly M, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Merle D, Ottman R, Clark LN,
35 RFPfeiffer
Marder K: The relation between depression and parkin genotype: the CORE-PD study. Parkinsonism and Related Disorders 17:740-744, 2011.
217. Puschmann A, Pfeiffer RF, Stoessl AJ, Kuriakose R, Lash JL, Searcy JA, Strongosky AJ, Vilariño-Güell C, Farrer MJ, Ross OA, Dickson DW, Wszolek ZK: A family with parkinsonism, essential tremor, restless legs syndrome and depression. Neurology 76:1623-1630, 2011.
218. Pankratz N, Dumitriu A, Hetrick KN, Sun M, Latourelle JC, Wilk JB, Halter C, Doheny KF, Gusella JF, Nichols WC, Myers RH, Foroud T, DeStefano AL; PSG-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories: Copy number variation in familial Parkinson disease. PLoS One 6:e20988, 2011.
219. Korff A, Pfeiffer B, Smeyne M, Pfeiffer RF, Smeyne RJ: Alterations in glutathione S- transferase pi expression following exposure to MPP+-induced oxidative stress in blood of Parkinson’s disease patients. Parkinsonism and Related Disorders 17:765-768, 2011.
220. Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, Mailman R, Chen H, Parkinson Study Group DATATOP Investigators: Serum cholesterol and the progression of Parkinson’s disease: results from DATATOP. PLoS One 6:e22854, 2011.
221. Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE, Parkinson Study Group DATATOP and PRECEPT Investigators: Predictors of time to requiring dopaminergic treatment in 2 Parkinson’s disease cohorts. Movement Disorders 26:608-613, 2011.
222. Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A, Parkinson Study Group PRECEPT Investigators: Serum urate and probability of dopaminergic deficit in early “Parkinson’s disease.” Movement Disorders 26:1864-1868, 2011.
223. Cannito MP, Suiter DM, Beverly D, Chorna L, Wolf T, Pfeiffer RF: Sentence intelligibility before and after voice treatment in speakers with idiopathic Parkinson’s disease. Journal of Voice 26:214-219, 2012.
224. Richard I, McDermott MP, Kurlan RM, Lyness JM, Como PG, Pearson NJ, Factor SA, Juncos JL, Serrano Ramos C, Brodsky MA, Manning C, Marsh L, Shulman LM, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer RF, Rottenberg DA, Slevin J, Elmer LW, Press D, Hyson C, McDonald W: A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson’s disease. Neurology 78:1229-1236, 2012.
225. Alcalay R, Caccappolo E, Mejia Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella C, Colcher A, Jennings D, Nance M, Bressman SB, Scott WK, Tanner C, Mickel SF, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman J, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Payami H, Molho E, Factor S, Ottman R, Clark LN, Marder K: Cognitive performance of GBA mutation carriers with early onset PD: the CORE-PD study. Neurology 78:1434-1440, 2012.
226. Pfeiffer RF: Autonomic dysfunction in Parkinson’s disease. Expert Review of Neurotherapeutics 12:697-706, 2012.
227. Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Ktainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T, PD GWAS Consortium. Meta-analysis of Parkinson’s disease: identification of a novel locus, RIT2. Annals of Neurology 71:370-384, 2012.
36 RFPfeiffer
228. Parkinson Study Group: Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson’s disease (STEADY-PD). Movement Disorders 28:1823-1831, 2013.
229. Cheshire WP, Pfeiffer RF: Is α-synuclein rising to the surface as a diagnostic marker for Parkinson disease? [Editorial]. Neurology 81:1568-1569, 2013.
230. Pfeiffer RF: Beyond here be dragons: SIBO in Parkinson’s disease. [Editorial]. Movement Disorders 28:1764-1765, 2013.
231. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang M-X, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella C, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Payami H, Molho E, Factor S, Nutt J, Serrano C, Arroyo M, Ottman R, Pauciulo M, Nichols W, Clark LN, Marder K: Cognitive and motor function in long duration PARKIN PD. JAMA Neurology 71:62-67, 2014.
232. Moonen AJ, Wijers A, Leentjens AF, Christine CW, Factor SA, Juncos J, Lyness JM, Marsh L, Panisset M, Pfeiffer R, Rottenberg D, Serrano Ramos C, Shulman L, Singer C, Slevin J, McDonald W, Auinger P, Richard IH. Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson’s disease. Parkinsonism and Related Disorders doi: 10.1016/j.parkreldis.2014.02.025, 2014 (epub ahead of print).
233. The Parkinson Study Group QE3 Investigators. A randomized clinical trial of high dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurology doi: 10.1001/jamaneurol.2014.131, 2014. (epub ahead of print).
234. Pfeiffer RF. Gastrointestinal involvement in Parkinson's disease: the horse or the cart? [Editorial]. Acta Physiologica (Oxford) 211:271-272, 2014.
235. Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, Hyson C, Jennings D, for the Parkinson Study Group PRECEPT Investigators: Longitudinal follow-up of SWEDD subjects in the PRECEPT study. Neurology 82:1791-1797, 2014.
ARTICLES ACCEPTED FOR PUBLICATION (IN PRESS):
236. Vemula SR, Xiao J, Zhao Y, Bastian RW, Perlmutter JS, Racette BA, Paniello RC, Wszolek ZK, Uitti RJ, Van Gerpen JA, Hedera P, Truong DD, Frei K, Blitzer A, Rudzińska M, Momčilović D, Jinnah H, Pfeiffer, RF, LeDoux MS. A rare sequence variant in intron 1 of THAP1 is associated with primary dystonia. Molecular Genetics and Genomic Medicine. In Press.
237. Theuns J, Verstraeten A, Sleegers K, Wauters E, Gijselinck I, Smolders S, Crosiers D, Corsmit E, Elnick E, Sharma M, Kruger R, Lesage S, Brice A, Chung SJ, Kim M-J, Kim YJ, Ross OA, Wszolek ZK, Rogaeva EA, Xi Z, Lang AE, Klein C, Weissbach A, Mellick GD, Silburn P, Hadjigeorgiou GM, Dardiotis E, Hattori N, Ogaki K, Tan E-K, Zhao YI, Aasly JO, Valente EM, Petrucci S, Annesi G, Quattrone A, Ferrarese C, Brighina L, Deutschländer A, Puschmann A, Nilsson C, Garraux G, LeDoux MS, Pfeiffer RF, Boczarska-Jedynak M, Opala G, Maraganore DM, Engelborghs S, De Deyn PP, Cras P, Cruts M, Van Broeckhoven C, on behalf of the GEO- PD consortium. Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease. Neurology. In Press.
37 RFPfeiffer
ARTICLES SUBMITTED FOR PUBLICATION:
1. Alcalay RN, Clark LN, Mejia-Santana H, Tang M-X, Rakitin B, Rosado L, Louis ED, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott W, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Ross B, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman J, Pfeiffer R, Marsh L, Ottman R, Marder K, Caccappolo E: Performance on the mini-mental state exam in carriers and non-carriers of Parkin mutations with early-onset Parkinson’s disease. (submitted).
2. Marek K, Seibyl J, Eberly S, Oakes D, Tabamo R, Shoulson I, Jennings D, and the Parkinson Study Group PRECEPT Investigators: Assessment of dopamine transporter imaging in the PRECEPT STUDY cohort after 22-month follow-up. (submitted).
3. Alcalay RN, Clark LN, Mejia-Santana H, Tang M-X, Rosado L, Louis ED, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Ross B, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman J, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Caccappolo E, Ottman R, Marder K: Demographic and clinical characteristics or LRRK2 G2019S carriers in early onset Parkinson disease. (submitted).
4. Marder K, Tang M-X, Mejia-Santana H, Rosado L, Louis ED, Comella C, Colcher A, Siderowf A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Ross B, Cote L, Frucht S, Ford B, Alcalay RN, Rezak M, Novak K, Friedman J, Pfeiffer R, Marsh L, Hiner B, Caccappolo E, Ottman R, Clark LN: Features associated with parkin mutation status in probands in the CORE-PD study. (submitted).
5. Hammond KG, Schilling BK, Pfeiffer RF, LeDoux MS. Neuromuscular rate of force development deficit in Parkinson’s disease. (submitted).
6. Sharp ME, Caccappolo E, Mejia-Santana H, Tang M-X, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella C, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Payami H, Molho E, Factor SA, Nutt J, Serrano C, Arroyo M, Ottman R, Pauciulo M, Nichols W, Clark LN, Alcalay RN, Marder KS. The relationship between obsessive-compulsive symptoms and PARKIN genotype: the CORE-PD study. (submitted).
BOOK REVIEWS:
1. Pfeiffer, R.F. NeUroGastroenterology. Movement Disorders 13:371, 1998.
2. Pfeiffer, R.F. Parkinson's Disease (Advances in Neurology, Vol 80). Movement Disorders 15:1301, 2000.
3. Pfeiffer, RF. Parkinson’s Disease and Movement Disorders. Annals of Neurology 49:821, 2001
4. Pfeiffer RF. Behavioral Neurology of Movement Disorders, 2nd Edition (Advances in Neurology, Vol 96). Annals of Neurology 59:217, 2006
ABSTRACTS PRESENTED AND PUBLISHED:
38 RFPfeiffer
1. Ebadi M, Pfeiffer RF: Decrease in brain pyridoxal phosphate by L-dopa and 5 hydroxytryptophan. Transactions of International Congress of Pharmacology 5:363, 1972.
2. Ebadi M, Pfeiffer RF, Johnson M: The antagonistic effect of pyridoxine on L-dopa-induced elevation of dopamine in the rat basal ganglia. Federation Proceedings 31:2112, 1972.
3. Teychenne PF, Pfeiffer RF, Bern SM, Calne DB: CF25-397 in parkinsonism. Neurology 27:406, 1977.
4. Pfeiffer RF, Wilken KE, Yates CS, Lorenzo AP: Low dose bromocriptine in Parkinson's disease. Neurology 33(2):112, 1983.
5. Pfeiffer RF, Wilken KE, Yates CS: CU32-085 in Parkinson's disease. Annals of Neurology. 14:135, 1983.
6. Schneider MB, Murrin LC, Pfeiffer RF: Effects of chronic L-dopa and bromocriptine treatment on dopamine receptors in an animal model of Parkinson's disease. Society for Neuroscience. Abstracts 9:719, 1983.
7. Pfeiffer RF, Wilken KE, Glaeske C: Long-term efficacy of mesulergine (CU32-085) in parkinsonism. Neurology 34(1):159, 1984.
8. Pfeiffer RF, Kenny AM, Schneider MB, Baden DR, Murrin LC: Effects of chronic administration, withdrawal, and reinstitution of bromocriptine on dopamine receptors in animal model of Parkinson’s disease. Neurology 35(1):118, 1985.
9. Pfeiffer RF, McComb RD: Dentatorubro-pallidoluysian atrophy with posterior column degeneration. Neurology 35(1):178, 1985.
10. Murrin LC, Schneider MB, Pfeiffer RF, Kenny AM, Deupree JD: Is contralateral rotation after unilateral nigral destruction due to dopamine receptor supersensitivity? VIII International Symposium on Parkinson's Disease: P114, 1985.
11. Pfeiffer RF, Schneider MB, Murrin LC, Kenny AM, Baden DR, Deupree JD: Chronic administration of dopamine agonists: Effects of both low and high doses on dopamine receptor binding. VIII International Symposium on Parkinson's Disease: P115, 1985.
12. Pfeiffer RF, Hsieh H, Diercks M, Jefferson A, Glaeske C: The dexamethasone suppression test in Parkinson's disease. VIII International Symposium on Parkinson's Disease: P130, 1985.
13. Pfeiffer RF, Sucha EL: On-off induced malignant hyperthermia. Annals of Neurology 18:138, 1985.
14. Fahn S, Shoulson I, and the Parkinson Study Group: Correlates of clinical decline in early Parkinson's disease. Neurology 37(1):278, 1987.
15. Pfeiffer RF: Bromocriptine-induced hypothermia. Neurology 37(1):282, 1987.
16. McComb RD, Pfeiffer RF: Pontine and extrapontine myelinolysis following liver transplantation: Relationship to serum sodium. Neurology 38(1):309, 1988.
17. Pfeiffer RF, Herrera L, Glaeske CS, Hofman RE: CQP 201-403: Long-term administration in patients with Parkinson's disease. Neurology 38(1):313, 1988.
39 RFPfeiffer
18. McComb RD, Pfeiffer RF, Casey JH, Wolcott G, Till DJ: Pontine and extrapontine myelinolysis associated with hypernatremia and hyperglycemia. Neurology 38(1):313, 1988.
19. Pfeiffer RF, Wilken KE, Glaeske CS: Sinemet CR4 in Parkinson's disease. Neurology 38(1):419, 1988.
20. Pfeiffer RF, Schneider MB, Kenny AM, Murrin LC: Long-term administration of dopamine agonists: Effects of both low and high doses on dopamine receptor binding. Archives of Neurology 45(2):207-208, 1988.
21. Shoulson I, and the Parkinson Study Group: Antioxidative experimental strategies for Parkinson's disease. The 9th International Symposium on Parkinson's Disease, Jerusalem, Israel, June 5-9, p. 19, 1988.
22. Shoulson I, and the Parkinson Study Group: Antioxidative experimental strategies aimed at slowing the progression of Parkinson's disease. Proceedings of The International Symposium on Alzheimer's Disease, June 12-15, 1988, Kuopio, Finland (World Federation of Neurology Research Group on Dementia) Publications of The University of Kuopio (ISBN 951-780-488-1), pp. 35-36, 1988.
23. Kurlan R, Clark S, Shoulson I, Penney J, and the Parkinson Study Group: Economic impact of protective therapy for early Parkinson's disease. Annals of Neurology 24:153, 1988.
24. Shimoda K, Pfeiffer RF, McComb RD, Yang H-YT: Development and characterization of primary culture of rat adrenal chromaffin cells. FASEB Journal 3:A871, 1989.
25. Pfeiffer RF, Kang J, Graber B, Wilson J: Clozapine for psychosis in Parkinson's disease. Neurology 39(3)(Suppl. 1):231, 1989.
26. Pfeiffer RF, Hofman R: CQA 206-291 in Parkinson's disease. Neurology 40(Suppl. 1):154, 1990.
27. Shoulson I, and the Parkinson Study Group: Deprenyl in early Parkinson's disease: Symptomatic versus protective efficacy. Neurology 40(Suppl. 1):153, 1990.
28. Oakes D, and the Parkinson Study Group: Progression of early Parkinson's disease until levodopa therapy is required. Neurology 40(Suppl. 1):378, 1990.
29. Edwards LE, Pfeiffer RF, Quigley E, Hofman R, Balluff M: Incidence of gastrointestinal symptoms in Parkinson's disease. Neurology 40(Suppl. 1):221, 1990.
30. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I, Stern M, Tanner C, Weiner W, and the Parkinson Study Group: Variable clinical expression of Parkinson's disease: Analysis of the DATATOP database. Neurology 40(Suppl. 1):168, 1990.
31. Wszolek Z, Pfeiffer RF, Rodnitzky RL, Schelper RL, Calne DB, Wolters ECh: Rapidly progressive autosomal dominant parkinsonism and dementia. Annals of Neurology 28:235, 1990.
32. Parkinson Study Group (P.G. Como, Presenter, Rochester, NY): Neuropsychological functioning in early untreated Parkinson's disease. Annals of Neurology 28:236, 1990.
33. Pfeiffer RF, Hofman R: CQA 206-291: Six months' experience in Parkinson's disease. Annals of Neurology 28(2):265, 1990.
40 RFPfeiffer
34. Environmental Influences Working Group of the Parkinson Study Group, and the Parkinson Study Group: Smoking and age at onset of Parkinson's disease: Analysis of the DATATOP cohort. Annals of Neurology 28:295, 1990.
35. Kieburtz K, Como P, McDermott M, and the Parkinson Study Group: Effect of deprenyl on neuropsychological function in early Parkinson's disease. Annals of Neurology 28:296, 1990.
36. Pelusio RM, Rudolph A, Orme C, Evans P, Plumb S, Oakes D, Shoulson I, and the Parkinson Study Group: DATATOP: Managing an accelerated trial. Controlled Clinical Trials 11:304, 1990.
37. Oakes D, McDermott M, Ebert S, Plumb S, Watts A, Shoulson I, and the Parkinson Study Group: Investigator effects in a multicenter trial for Parkinson's disease. Controlled Clinical Trials 11:284, 1990.
38. Hall WJ, Oakes D, and the Parkinson Study Group: Statistical issues in monitoring a 2 x 2 factorial clinical trial. Controlled Clinical Trials 11:264, 1990.
39. LeWitt PA, Galloway M, Oakes D, Watts A, Mattson W, and the Parkinson Study Group; Homovanillic Acid, other monoamine metabolites, and xanthine in parkinsonian CSF. Neurology 41 (Suppl 1): 379, 1991
40. Pelusio RM, Miller C, Orme C, Andrews M, Casaceli C, Lieou J, Kieburtz K, Wixsom J, Shoulson I, and the Parkinson Study Group: Use of computer applications to facilitate retroactive updates to a database. Controlled Clinical Trials 12:707, 1991.
41. Bhatt MH, Wszolek Z, Wolters ECh, Pfeiffer RF, Snow BJ, Rodnitzky RL, Calne DB: Parkinsonism and dementia due to pallido-ponto-nigral degeneration: A positron emission tomography study. 10th International Symposium on Parkinson's Disease Book of Abstracts 177, 1991.
42. Wszolek ZK, Pfeiffer RF, Rodnitzky RL, Calne DB, Schelper RL: Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration. 10th International Symposium on Parkinson's Disease Book of Abstracts 246, 1991.
43. Ebadi M, Pfeiffer RF, Iversen PL, Murrin LC: Reduced levels of striatal zinc and metallothionein in 6-hydroxydopamine-lesioned rats. Transactions of the Western Pharmacology Society 1991 Annual Meeting 34:24, 1991.
44. Edwards L, Quigley EMM, Harned RK, Hofman R, Pfeiffer RF: Follow-up study of gastrointestinal symptoms in Parkinson's disease. Annals of Neurology 30:259, 1991.
45. Edwards L, Quigley EMM, Harned RK, Hofman R, Pfeiffer R: Characterization of swallowing and defecation in Parkinson's disease. Annals of Neurology 30:259, 1991.
46. Wszolek ZK, Fulgham JR, Aksamit AJ, Ellingson RJ, Sharbrough FW, Westmoreland BF, Pfeiffer RF: Epileptiform EEG abnormalities in liver transplant recipients. Annals of Neurology 30:292, 1991.
47. Ebadi M, Pfeiffer RF: The role of metallothionein in oxidative stress and free radical metabolism in neurons. Journal of Neurochemistry 57:S75, 1991.
48. Kang J, Pfeiffer R, Graber B, Wilson J, Kaur P: Treatment of iatrogenic psychosis in Parkinson's disease with clozapine. Biological Psychiatry 29:245S, 1991.
41 RFPfeiffer
49. McManis PG, Wszolek ZK, Herkes GK, Pfeiffer RF, Calne DB, Rodnitzky RL: Tremor studies in patients with rapidly progressive autosomal dominant parkinsonism and dementia. Muscle & Nerve 14: 874, 1991.
50. Pfeiffer RF, Shiraga H, Lintz J, Ebadi M: The involvement of zinc metallothionein in protecting against deleterious actions of iron, hydrogen peroxide, and reactive oxygen in striatal neurons of an animal model of Parkinson's disease. 10th International Symposium on Parkinson's Disease Book of Abstracts 113, 1991.
51. Pfeiffer RF, Ebadi M: Vulnerability of striatal dopaminergic neurons to free radicals: The protective effects of zinc and metallothionein. Society for Neuroscience Abstracts 17:1288, 1991.
52. Ebadi M, Perini F, Pfeiffer RF, Paliwal VK, Garvey JS, Mountjoy K: Amino acid composition, immunoreactivity, and sequence analysis of bovine hippocampal metallothionein isoforms. Society for Neuroscience Abstracts 17:246, 1991.
53. Shiraga H, Pfeiffer RF, Ebadi M: Dopamine-mediated and zinc metallothionein modulated oxidative stress in Parkinson's disease. Pharmacologist 34:108, 1992.
54. Wszolek Z, Cordes M, Rodnitzky RL, Pfeiffer RF, Calne DB: MRI examinations in autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration. Movement Disorders 7(suppl):151, 1992.
55. Cordes M, Wszolek Z, Rodnitzky RL, Pfeiffer RF, Calne DB: MRI examinations in autosomal- dominant parkinsonism and dementia with pallido-ponto-nigral degeneration. Neurology 42(suppl 3):154, 1992.
56. Wszolek Z, Cordes M, Lee C, Cordes I, Muenter MD, Pfeiffer RF, Calne DB: Three families with dominantly inherited parkinsonism. Annals of Neurology 32:275, 1992.
57. Edwards L, Quigley E, Harned R, Hofman R, Pfeiffer R: Gastrointestinal dysfunction in Parkinson's disease. Movement Disorders 7 (suppl):84, 1992.
58. Pfeiffer RF, Edwards LL, Harned RK, Quigley EMM, Hofman R: Effect of apomorphine on swallowing and defecation in Parkinson's disease. Annals of Neurology 32:276, 1992.
59. McManis PG, Wszolek ZK, Herkes GK, Pfeiffer RF, Calne DB, Rodnitzky RL: Tremor studies in patients with rapidly progressive autosomal dominant parkinsonism and dementia. Electroencephalography and Clinical Neurophysiology 85:1P-2P, 1992.
60. Hao R, Pfeiffer RF, Ebadi M: Activation of pyridoxal kinase by zinc metallothionein in trout brain. Society for Neuroscience Abstracts 18:1300, 1992.
61. Byrne KG, Pfeiffer RF, Quigley EMM: Gastrointestinal dysfunction in Parkinson's disease. American Journal of Gastroenterology 87: 1336, 1992.
62. LeWitt P, Galloway M, Matson W, McDermott M, Oakes D, and the Parkinson Study Group: Markers of endogenous dopamine synthesis in Parkinson's disease. Neurology 42(Suppl 3):421, 1992
63. Pelusio RM, Wixsom J, Rudolph A, Orme C, Shoulson I, and the Parkinson Study Group: Subject file checklists to facilitate clinical trial closeout activities. Controlled Clinical Trials 13:438, 1992.
42 RFPfeiffer
64. LeWitt P, Galloway M, Matson W, Milbury P, McDermott M, Oakes D, Shoulson I, and the Parkinson Study Group (DATATOP Study): Society for Neuroscience Abstracts 18:1248, 1992.
65. McDermott MP, Jankovic J, and the Parkinson Study Group. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. Neurology 41(Suppl 3):441, 1992.
66. Stallwood D, Shiraga H, Ebadi M, Pfeiffer R, Landers D, Paul S: Is calmodulin a neuropeptide receptor? FASEB Journal. 7:1054, 1993.
67. Samejima M, Happe HK, Murrin LC, Pfeiffer RF, Ebadi M: Autoradiographic localization of cholinergic and dopaminergic receptors in trout pineal gland. FASEB Journal. 7:2282, 1993.
68. Hao R, Cerutis DR, Blaxall HS, Rodriquez-Sierra JF, Pfeiffer RF, Ebadi M: Distribution of metallothionein mRNA in the rat brain using in situ hybridization. FASEB Journal. 7:482, 1993.
69. Ebadi M, Hao R, Cerutis DR, Blaxall HS, Pfeiffer RF: Zinc fingers, metallothionein, and neurotrophic activity in brain. International Symposium on "Immune-neuroendocrine communication in growth and development", Tubingen, Germany. Neuroendocrinology Letters 15(3):166, 1993.
70. Samejima M, Happe HK, Murrin LC, Pfeiffer RF, Ebadi M: Distribution of dopamine receptors in trout pineal gland. Japanese Journal of Physiology 55:25, 1993.
71. Wszolek Z, Normand M, Langerlund T, Pfeiffer RF, McManis P: Electrophysiologic findings in patients with rapidly progressive familial parkinsonism and dementia with pallido-ponto-nigral degeneration. Electroencephalography and Clinical Neurophysiology. 87:S35, 1993.
72. Wszolek Z, Normand M, Langerlund T, Pfeiffer RF: EEG Background frequency analysis in patients with rapidly progressive autosomal dominant parkinsonism and dementia with pallido- ponto-nigral degeneration. Muscle Nerve. 16:1126, 1993.
73. Wijker M, Wszolek ZK, Wolters ECh, Pais G, Pfeiffer RF, Rodnitzky RL, Arwert F: Genetic linkage analysis in rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration (RPADP). American Journal of Human Genetics 53 (Supplement): 1721, 1993.
74. Wszolek ZK, Pfeiffer B, Fulgham JR, Parisi JE, Thompson BM, Uitti RJ, Calne DB, Pfeiffer RF: Western Nebraska family (Family D) with autosomal dominant Parkinson's disease. Annals of Neurology 34:264, 1993.
75. Ebadi M, Blaxall HS, Bylund DB, Prapapanich V, Heck DA, Pfeiffer RF: Cloning of alpha2 adrenergic receptor subtypeD in the bovine pineal gland. Proceedings of the European Pineal Society, 6:93, Copenhagen, Denmark, 1993 .
76. Ashraf W, Pfeiffer RF, Quigley EMM: An evaluation of the specificity of anorectal manometry in Parkinson's disease. Interdisciplinary International Symposium on GI Dysfunction in Neurological Diseases, 1993.
77. Wszolek ZK, Sison AS Jr, Denson MA, Pfeiffer RF, Calne DB: Genealogic studies of familial parkinsonism. New Trends in Clinical Neuropharmacology 7:140, 1993
43 RFPfeiffer
78. Wszolek ZK, Normand M, Lagerlund TD, Pfeiffer RF: EEF background frequency analysis in patients with rapidly progressive autosomal dominant parkinsonism and dementia with pallido- ponto-nigral degeneration. Electroencephalography and Clinical Neurophysiology 90:5, 1993.
79. Hao R, Norgren RB, Rodriguez-Sierra JF, Ebadi M, Pfeiffer RF: Neurofilaments maintain the structural and functional integrity of dopaminergic neurons in culture. Society for Neuroscience Abstracts 19:1049, 1993.
80. Ebadi M, Samejima M, Pfeiffer RF: Pineal gland in synchronizing and refining physiological events. Journal of Pineal Research 16(1):37-43, 1994.
81. Ashraf W, Pfeiffer RF, Quigley EMM: Squeeze profile is a specific measure of defecatory dysfunction in Parkinson's disease. Journal of GI Motility, 1994.
82. Hao R, Norgren RB, Pfeiffer RF: Cerebrospinal fluid (CSF) from individuals with Parkinson's disease inhibits dopaminergic neuron growth and function in vitro. Neurology. 44 (suppl 2): A154, 1994.
83. Denson MA, Wszolek ZK, Pfeiffer RF: Danish-American family (Family E) with "Parkinson's disease": Pitfalls of genetic studies of PD. Neurology 44 (suppl 2):A247, 1994.
84. Strickland D, Bertoni J, Pfeiffer RF: Parkinson's disease and agricultural factors in Nebraska. Neurology 44 (suppl 2):A136, 1994.
85. Pfeiffer RF, Bennett D: Amantadine induced laryngeal (vocal) myoclonus. Neurology 44 (suppl 2):A305, 1994.
86. Cordes M, Wszolek ZK, Pfeiffer RF, Calne DB: PET untersuchungen der prasynaptischen dopaminergen funtion bei autosomal-dominant verbtem parkinsonismus mit demenz und pallido- ponto-nigraler degeneration (PPND). Nuklear Medizin 33:p62, 1994.
87. Markopoulou K, Wszolek ZK, Pfeiffer RF: A Greek-American family with autosomal dominant levodopa responsive parkinsonism. Annals of Neurology 36:280, 1994.
88. Denson MA, Wszolek ZK, Pfeiffer RF: Volga German-American family (Family G) with inherited parkinsonism. Annals of Neurology 36:281, 1994.
89. Singaram C, Ashraf W, Pfeiffer RF, Quigley EMM: Enteric nervous system (ENS) involvement in Parkinson's disease: Immunohistochemical evidence of dopamine depletion and Lewy body formation in the colon of patients with Parkinson's disease (PD). Gastroenterology 107:1232, 1994.
90. Ashraf W, Wszolek ZK, Pfeiffer RF, Normand M, Srb F, Edwards LL, Quigley EMM: Variations in anorectal function in relation to on-off fluctuations in Parkinson's disease. Gastroenterology 107:1232, 1994.
91. Singaram C, Ashraf W, Quigley EMM, Pfeiffer RF: Enteric nervous system (ENS) dopamine depletion in Parkinson's disease (PD): Immunohistochemical studies. Movement Disorders 9 (suppl 1):100, 1994.
92. Ashraf W, Wszolek ZK, Quigley EMM, Normand M, Srb F, Edwards LL, Pfeiffer RF: Anorectal function during motor fluctuations in Parkinson's disease. Movement Disorders 9 (suppl 1): 96, 1994.
44 RFPfeiffer
93. Wszolek ZK, Denson MA, Markopoulou K, Pfeiffer RF: Genealogic investigations of familial parkinsonism. Movement Disorders 9 (suppl 1): 81, 1994.
94. Supala A, Wszolek ZK, Trofalter J, Ozelius L, Vitti RJ, Lee CS, Gusella J, Pfeiffer RF, Calne DB, Breakefield XO, Gasser T: Genetic linkage studies in autosomal dominant parkinsonism: Evaluation of candidate genes. Movement Disorders. 9 (suppl 1):32, 1994.
95. Gasser T, Wszolek ZK, Trofalter J, Ozelius L, Lee C, Gusella J, Pfeiffer RF, Calne DB, Breakefield XO: Genetic linkage studies in autosomal dominantly inherited L-dopa responsive parkinsonism: Evaluation of candidate genes. New Trends in Clinical Neuropharmacology 8:45, 1994
96. Hutton JT, Hurtig H, Hiner B, Koller W, Lieberman A, Ahlskog J, Pfeiffer R, Rodnitzky R, Waters C, Muenter M: Multicenter, placebo-controlled study of cabergoline taken once daily in the treatment of Parkinson’s disease. Neurology 45(suppl 4):A203, 1995.
97. Hao R, Ebadi M, Han H, Lintz J, Pfeiffer RF: Selegiline protects dopaminergic neurons in culture from toxic factor(s) in cerebrospinal fluid of Parkinson’s disease patients. Neurology 45(suppl 4):A251, 1995.
98. Bodis-Wollner I, Antal A, Pfeiffer R: Visuo-cognitive processing in non-demented parkinsonian patients: An event-related potential study. Neurology 45(suppl 4):A340, 1995.
99. Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EMM: Constipation in Parkinson’s disease: Response to psyllium. Gastroenterology 108:A564, 1995.
100. Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EMM: An objective assessment of constipation in Parkinson’s disease. Gastroenterology 108:A564, 1995.
101. Singaram C, Ashraf W, Sengupta A, Pfeiffer RF, Quigley EMM: Specific loss of colonic myenteric dopaminergic neurons in constipated patients with Parkinson’s disease. Gastroenterology 108:A691, 1995.
102. Widman LP, Burke WJ, Pfeiffer RF, McArthur-Campbell D: Use of clozapine to treat levodopa- induced psychosis in Parkinson’s disease: A retrospective review. American Association of Geriatric Psychiatry, 1995.
103. Wszolek ZK, Denson MA, Wszolek EK, Markopoulou K, Lang AE, Pfeiffer RF: Smell testing in familial parkinsonism. Journal of Neurology 242 (Suppl 2):S78, 1995.
104. Gasser T, Supala A, Wszolek Z, Muller B, Bennett P, Pfeiffer RF, Calne D: Genetic linkage studies in autosomal dominantly inherited L-dopa responsive parkinsonism. Journal of Neurology 242 (Suppl 2):S16-1995.
105. Markopoulou K, Pfeiffer RF, Wszolek ZK, Chase BA: Is familial parkinsonism associated with the expansion of trinucleotide repeats? Society for Neuroscience Abstracts 21:1248, 1995.
106. Hao R, MacDonald RG, Ebadi M, Schmit JC, Pfeiffer RF: Interaction between actin and neurofilaments. Society for Neuroscience Abstracts 21:48, 1995.
107. Baxi M, Hiramatsu M, Ahmad I, El Refaey H, Helal G, Hamada FM, Hao R, Pfeiffer RF, Rojas P, Cerutis DR, Ebadi M: The expression, regulation, and functions of hippocampal specific metallothionein isoform. Society for Neuroscience Abstracts 22:1453, 1996.
45 RFPfeiffer
108. Hao R, Kalabokis V, Fu LS, Iverson PL, Ebadi M, Pfeiffer RF: Reduction of neurofilament light subunit alters the distribution and amount of F-actin in dopaminergic neurons. Society for Neuroscience Abstracts 22:1985, 1996.
109. Wengel SP, Burke WJ, Roccaforte WH, Pfeiffer R, Paige SR: Maintenance ECT for intractable Parkinson’s disease. American Psychiatric Association Abstracts p 212, 1996.
110. Siddiqui MF, Rast S, Pfeiffer RF: Assessment of autonomic dysfunction in Parkinson’s disease. Neurology 46:A378, 1996.
111. Hao R, Pfeiffer RF, Bishop J, Lau V, Mouradian MM: BDNF Is essential for dopaminergic neuronal function and growth in vitro. Neurology 46:A444, 1996.
112. Richard I, Kurlan R, Tanner C, and the Parkinson Study Group: Serotonin syndrome and the combined use of deprenyl as an antidepressant in Parkinson’s Disease. Neurology 46:A374, 1996.
113. Wszolek ZK, Markopoulou K, Larsen K, Pfeiffer RF: Familial parkinsonism - genealogical studies. A ten year experience. Movement Disorders 12(suppl 1):3, 1997.
114. Hao R, Lau YS, Fu L, Anderson TM, Pfeiffer RF: Dopamine and neurotoxicity of CSF from PD patients. Movement Disorders 12 (suppl 1):42, 1997.
115. Hao R, Lau V, Fu L, Anderson TM, Pfeiffer RF: Neurotoxicity in cerebrospinal fluid from untreated and selegiline treated Parkinson’s disease patients. Neurology 48:A186, 1997.
116. Lau Y-S, Hao R, Fung YK, Bishop JF, Pfeiffer RF, Mouradian MM: Effects of BDNF antisense oligodeoxynucleotide (ODN) on nigrostriatal dopaminergic activity. ASPET, 1997.
117. Welsh M, McDermott M, Holloway R, Plumb S, Pfeiffer R, Hubble J (Parkinson Study Group Quality of Life Task Force): Development and testing of the Parkinson’s disease quality of life scale: the PDQUALIF. Movement Disorders 12:836, 1997.
118. Parkinson Study Group (Shoulson I, primary author): Clinical outcome following placebo- controlled withdrawal of deprenyl (selegiline) among levodopa-treated DATATOP subjects. Movement Disorders 12:838, 1997
119. Rajput AM, Jankovic J, McDermott M, and the Parkinson Study Group. Diagnostic accuracy in early Parkinson’s disease. Neurology 47:A369, 1997.
120. Panisset M, Siderowf A, McDermott M, Kieburtz K, Friedman J, Growdon J, and the Parkinson Study Group. Baseline predictors of subsequent dementia in the DATATOP cohort. Movement Disorders 12:836, 1997.
121. Rashed H, Abell TL, Cardoso S, Pfeiffer R: Case report: The effect of domperidone on autonomic nervous system function in a patient with Parkinson's disease. Clinical Autonomic Research 1998.
122. Hao R, Fu LS, Pfeiffer R: Abnormal protein found in CSF from PD patients by 2D-gel electrophoresis. Neurology 50:A386, 1998.
123. Abell T, Rashed H, Cardoso S, Pfeiffer RF: Domperidone improves GI and autonomic nervous system function in Parkinson's disease. Neurology 50:A278-279, 1998.
46 RFPfeiffer
124. Parkinson Study Group: Low dose clozapine for the treatment of drug-induced psychosis (DIP) in idiopathic Parkinson's disease (PD): Results of the double-blind placebo-controlled PSYCLOPS trial. Neurology 50:A70, 1998.
125. Factor SA and the Parkinson Study Group: Clozapine for the treatment of drug induced psychosis in Parkinson's disease: results of the 12 week open label follow up in the PSYCLOPS trial. Movement Disorders 13 (Suppl 2):241, 1998.
126. Parsa M, Friedman J, Oakes D, Greenaway H, and the Parkinson Study Group: Phenomenology of levodopa-induced psychosis in Parkinson's disease. Ninth Congress of the International Psychogeriatric Association. Abstract Booklet:137, 1999.
127. Parkinson Study Group: The Glutamate antagonist remacemide improves motor performance in levodopa-treated Parkinson's disease. Neurology 52:A262, 1999.
128. Wszolek ZK, Gwinn-Hardy KA, Muenter MD, Pfeiffer RF, McComb RD, Gasser T, Dickson DW: Family C (German-American) with late onset parkinsonism: Longitudinal observations including autopsy. Neurology 52:A221, 1999.
129. Parkinson Study Group: Pramipexole in ethnic minorities with Parkinson's disease (PD): Safety, tolerability, and efficacy (PRIME). Movement Disorders 14:901, 1999.
130. Holloway R, McDermott M, Kieburtz K, Penney J (deceased), Fahn S, Lang AE, Shoulson I, and the Parkinson Study Group: Estimating the incidence of motor complications in patients starting levodopa: Implications for clinical trials. Movement Disorders 14:905, 1999.
131. Parkinson Study Group (Holloway R, primary author): Pramipexole versus levodopa in early Parkinson's disease: A randomized clinical trial. Neurology 54(Suppl3):A89, 2000.
132. Parkinson Study Group (Marek K, primary author): ß-CIT-SPECT assessment of progression of Parkinson's disease in subjects participating in the CALM-PD study. Neurology 54(Suppl 3):A90, 2000.
133. Parkinson Study Group (Marek K, presenter): Comparison of imaging and clinical endpoints in subjects participating in the CALM-PD study. Neurology 56:A73, 2001.
134. Parkinson Study Group (Kieburtz K, presenter): Dopamine agonists in the prevention and treatment of motor complications: CALM-PD. Parkinsonism and Related Disorders 2001.
135. Parkinson Study Group (deMarcaida JA, presenter): Current opinions on appropriate endpoints in Parkinson’s disease-modifying trials. Movement Disorders 16:989-990, 2001.
136. Parkinson Study Group (Reider CR, presenter): Reliability of self-reporting age of onset for Parkinson’s disease. Movement Disorders 16:991-992, 2001.
137. Parkinson Study Group (Holloway RG, presenter): Pramipexole versus levodopa as initial treatment for Parkinson’s disease: A four-year randomized controlled trial. Neurology 58(Suppl 3):A81-A82, 2002.
138. Parkinson Study Group (Marek K, presenter): Pramipexole versus levodopa: Effects on Parkinson disease progression assessed by dopamine transported imaging. Neurology 58(Suppl 3):A82, 2002.
47 RFPfeiffer
139. Reider C, Halter C, Castelluccio P, Foroud T, and the Parkinson Study Group: Differences in duration from parkinsonian symptom onset to diagnosis among concordantly affected siblings. Neurology 58(Suppl 3):A108, 2002.
140. Nichols WC, Pankratz ND, Uniacke SK, Pauciulo MW, Halter C, Rudolph A, Conneally PM, Foroud T, and the Parkinson Study Group: Stratification by linkage rather than age of onset identifies more parkin mutation positive PD families. Neurology 58(Suppl 3):A409-A410, 2002.
141. Wszolek ZK, Pfeiffer RF, Tsuboi Y, McComb RD, Uitti RJ, Dickson DW, Strongosky A, Farrer M, Gasser T: Late-onset autosomal dominant familial Parkinson’s disease. Clinico-pathological study of Western Nebraska family (Family D). Movement Disorders 17(Suppl 5):S119, 2002.
142. Pfeiffer RF, Markopoulou K, Quigley EMM, Stambler N, Cedarbaum JM: Effect of NT-3 on bowel function in Parkinson’s disease. Movement Disorders 17(Suppl 5):S223-S224, 2002.
143. Friedman JH, Messing S, Oakes D, Breier A, Feldman PD, and the Parkinson Study Group: A descriptive and comparative analysis of psychotic symptoms in three placebo-controlled, double-blinded trials of atypical antipsychotic drugs in the treatment of drug-induced psychosis in Parkinson’s disease. Movement Disorders 17:1105, 2002.
144. Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R, and the Parkinson Study Group: Longitudinal outcome of Parkinson’s disease patients with psychosis: Persistence of behavioral impairments, mortality and nursing home placement. Movement Disorders 17:1105-1106, 2002.
145. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, Shults C, Conneally PM, Nichols WC, and the Parkinson Study Group: Identification and characterization of parkin mutations among later-onset familial Parkinson’s disease subjects. Annals of Neurology 52(Suppl 1):S37, 2002.
146. Blindauer K, and the Parkinson Study Group: Delayed response to levodopa and response failures account for a large percentage of daily off time in advanced Parkinson’s disease patients with motor fluctuations. Neurology 60(Suppl 1):A81-A82, 2003.
147. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, and the Parkinson Study Group: PARK3 and PARK7 linked to age of onset of Parkinson disease. Neurology 60(Suppl 1):A127, 2003.
148. Nichols WC, Pankratz N, Uniacke SK, Reed T, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, and the Parkinson Study Group: Lack of association of homozygosity for the 7048G7049 intron six Nurr1 gene polymorphism in 322 families with Parkinson disease. Neurology 60(Suppl 1):A281-A282, 2003.
149. Wszolek ZK, Tsuboi Y, Uitti RJ, Strongosky A, Farrer MJ, Dickson DW, Pfeiffer RF, Gasser T, McComb RD, Zimprich A, Müller-Myhsok B, Calne DB: PARK8 locus is associated with late- onset autosomal dominant parkinsonism. Clinical, pathological and linkage analysis study of Family A & D. Neurology 60(Suppl 1):A282-A283, 2003.
150. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Parkinson Study Group: Evidence for a gene on chromosome 10 that influences both PD and AD susceptibility. Neurology 62(Suppl 5):A27, 2004.
48 RFPfeiffer
151. Pfeiffer RF, the APO-302 Investigators: Continued effect of intermittent subcutaneous apomorphine following long-term use in patients with advanced Parkinson’s disease. Movement Disorders 19(Suppl 9):S281, 2004.
152. Kieburtz K, Romer M, McDermott M, Kamp C, Parkinson Study Group: Impact of pramipexole on mood and initiative in early Parkinson’s disease. Movement Disorders 20(Suppl 10):S121, 2005.
153. Pfeiffer RF, Ransmayr G: Gastrointestinal dysfunction in Parkinson’s disease. Parkinsonism and Related Disorders 11 (Suppl 2):96, 2005.
154. Pfeiffer RF: Apathy, withdrawal, and personality change in Parkinson’s disease. Movement Disorders 21 (Suppl 13):S16, 2006.
155. Parkinson Study Group PRECEPT Investigators: Baseline comparison of the PRECEPT and DATATOP clinical trial cohorts. Movement Disorders 21 (Suppl 13):S121, 2006.
156. Parkinson Study Group, Tanner CM: Follow-Up of persons with Neurologic Diseases (FOUND). Movement Disorders 21 (Suppl 13):S127, 2006.
157. Constantinescu R, Romer M, Kieburtz K, The DATATOP Parkinson Study Group Investigators: Malignant melanoma in early Parkinson’s disease. Movement Disorders 21(Suppl 13):S120, 2006
158. Pourcher E and the 6002-US-018 Clinical Investigator Group: Safety and tolerability of istradefylline (KW-6002) in Parkinson’s disease with motor response complications: results of the KW-6002-US-018 study. Movement Disorders 21(Suppl 15):S508, 2006.
159. Guttman M and the US-018 Clinical Investigator Group: Efficacy of istradefylline in Parkinson’s disease patients treated with levodopa with motor response complications: results of the KW-6002-US-018 study. Movement Disorders 21 (Suppl 15):S585, 2006.
160. Fernandez HH and the US-018 Clinical Investigators: Istradefylline for the treatment of motor response complications on levodopa in PD patients: results of the KW-6002-US-018 study focusing on functional and motor improvement. Movement Disorders 21 (Suppl 15):S643, 2006.
161. Pankratz N, Halter C, Rudolph A, Shults C, Nichols W, Foroud T, Parkinson Study Group – PROGENI Investigators: Depression in a cohort of 1335 individuals with familial Parkinson disease. Neurology 68:A37, 2007.
162. Biglan KM, Brocht A, McDermott MP, Kieburtz K, Parkinson Study Group CALM-PD Investigators: Identifying predictors of somnolence and edema in patients with early Parkinson’s disease treated with pramipexole: a secondary analysis of the CALM-PD study. Movement Disorders 22:S231, 2007.
163. Biglan KM, Brocht A, McDermott MP, Kieburtz K, Parkinson Study Group CALM-PD Investigators: Identifying predictors of response to pramipexole treatment in early Parkinson’s disease: a secondary analysis of the CALM-PD study. Movement Disorders 22:S232, 2007.
164. Marder K, Clark L, Mejia-Santana H, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott W, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Fraser J, Rosado L, Cote L, Caccappolo E, Frucht S, Ford B, Novak K, Friedman J, Pfeiffer R, Tang M-X, Ottman R.
49 RFPfeiffer
Features associated with Parkin mutation status in probands in the CORE-PD study. Annals of Neurology 62 (Suppl 11):S38, 2007.
165. Alcalay RN, Caccappolo E, Maroof D, Clark L, Mejia-Santana H, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott W, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Rosado L, Cote L, Frucht S, Ford B, Novak K, Rezak M, Siderowf A, Friedman JH, Pfeiffer R, Tang M-X, Ottman R, Marder K. Performance on the mini-mental state exam in carriers and non-carriers of Parkin mutations. Movement Disorders 23 (Suppl 1):S97-S98, 2008.
166. Schilling BK, LeDoux MS, Pfeiffer, RF, Karlage RE, Weiss, LW, Falvo, MJ: Effects of lower- body resistance training in persons with Parkinson’s disease. Movement Disorders 23:S211, 2008.
167. Uc EY, McDermott MP, Growdon JC, Marder KS, Anderson SW, Litvan I, Como P, Chou KL, and the Parkinson Study Group. Incidence and predictors of dementia in early Parkinson’s disease: results from the DATATOP study. Annals of Neurology 64(Suppl 12):S2, 2008.
168. LeDoux M, Xiao J, Bastian RW, Perlmutter J, Racette B, Tabbal S, Karimi M, Paniello R, Blitzer A, Batish SD, Wszolek Z, Uitti R, Hedera P, Simon D, Tarsy D, Truong D, Frei K, Pfeiffer R, Gong S, Zhao Y. High-throughput mutational analysis of TOR1A in primary dystonia. Neurology 72 (Suppl 3):A273, 2009.
169. Uc EY, McDermott MP, Weintraub D, Marsh L, Growdon J, Chou K, Auinger P, Marder K, Parkinson Study Group. Predictors of depression in early Parkinson’s disease. Neurology 72:A257-A258, 2009.
170. Alcalay RN, Clark LN, Mejia-Santana H, Tang M, Rosado LE, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Ross BM, Cote LJ, Frucht S, Rezak M, Ford B, Novak K, Friedman J, Pfeiffer R, Marsh L, Caccappolo EA, Hiner B, Siderowf A, Ottman R, Marder K. Demographic and clinical characteristics of LRRK2 G2019S carriers in early onset PD. Neurology 72 (Suppl 3):A389, 2009.
171. Ravina B, Tanner C, DiEuliis D, Flagg E, Shoulson I, Parkinson Study Group LABS-PD Investigators. A longitudinal program for biomarker development in Parkinson’s disease. Movement Disorders 24(Suppl 1):S275, 2009.
172. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Ross B, Kisselev S, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott W, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman J, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Marder K, Clark L. Frequency and phenotypic characteristics of PRKN, LRRK2, PINK1 and DJ1 mutation carriers in early onset PD: The CORE-PD study. Neurology 74(Suppl 2):A2, 2010.
173. Srivastava A, Tang M, Louis E, Mejia-Santana H, Ottman R, Rosado L, Marder K, Comella C, Bressman S, Nance M, Siderowf A, Jennings D, Colcher A, Scott W, Waters C, Cote L, Andrews H, Tanner C, Mickel S, Fahn S, Ross B, Frucht S, Verbitsky M, Ford B, Kisselev S, Alcalay R, Rezak M, Novak K, Neils G, Friedman J, Pfeiffer R, Marsh L, Hiner B, Clark LN, Caccappolo EA. Depression among carriers and non carriers of Parkin mutations. Neurology 74(Suppl2):A114, 2010.
174. Xiao J, Zhao Y, Bastian RW, Perlmutter JS, Racette BA, Tabbal SD, Karimi M, Paniello RC, Wszolek ZK, Uitti RJ, Van Gerpen JA, Simon DK, Tarsy D, Hedera P, Truong DD, Frei KP, Batish SD, Blitzer A, Pfeiffer RF, Le C, Akano E, LeDoux MS. A rare sequence variant in
50 RFPfeiffer
intron 1 of THAP1 is associated with primary dystonia. Movement Disorders 25(Suppl2):S240, 2010.
175. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner W, Siderowf A, Ottman R, Clark LN, Marder KS. Neuropsychological performance of early onset PD cases with and without GBA mutations: The CORE-PD study. Movement Disorders 25(Suppl2):S312, 2010.
176. LeDoux MS, Xiao J, Zhao Y, Bastian RW, Perlmutter JS, Racette BA, Tabbal SD, Karimi M, Paniello RC, Wszolek ZK, Uitti RJ, Van Gerpen JA, Simon DK, Tarsy D, Hedera P, Truong DD, Frei K, Batish SD, Blitzer A, Pfeiffer RF, Le C, Akano E. The c.-237_236GA>TT THAP1 sequence variant is not associated with a significantly increased risk for primary dystonia. Movement Disorders 25(Supple2):S476, 2010.
177. Alcalay R, Rosado L, Siderowf A, Ottman R, Caccappolo E, Mejia-Santana H, Tang M, Louis E, Ruiz D, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Orbe-Reily M, Ross B, Verbitsky M, Kisselev S, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott W, Tanner C, Mickel S, Rezak M, Novak K, Friedman J, Pfeiffer R, Marsh L, Hiner B, Clark L, Marder K. Olfaction in glucocerebrosidase mutation carriers with and without PD. Neurology 76(Suppl4):A490, 2011.
COMMITTEES AND OFFICES HELD:
Memberships in Professional Societies:
1988-present American Neurological Association 1975-present American Academy of Neurology 1986-present Parkinson Study Group 1986-present Movement Disorder Society 1986-present Society for Neuroscience 1985-1992 Central Society for Neurological Research 1980-1994 Nebraska Academy of Neurologists & Neurosurgeons 1984-1985 President - Nebraska Academy of Neurologists & Neurosurgeons 1986-1994 Omaha Mid-West Clinical Society 1987-1993 Association of University Professors of Neurology
COMMITTEE ASSIGNMENTS: UNIVERSITY OF TENNESSEE:
Departmental: 1994-present Residency Committee 1994-present Student Teaching Committee 1997-present Promotion and Tenure Committee
University: 1997-2006 Member, Dean’s Faculty Advisory Committee 2001-2002 Chairman, Deans Faculty Advisory Committee
VA Medical Center 1997 Search Committee (Radiology Chief)
51 RFPfeiffer
Regional Medical Center 1999-2005 Member, Ethics Committee
UNIVERSITY OF NEBRASKA: Departmental: 1981-1986 Patient Care Committee (Chairman) 1981-1987 Promotion and Tenure Committee 1986-1987 Residency Committee 1986-1987 Finance & Administration Committee
University: 1983-1989 Institutional Review Board 1983-1985 Clinical Affairs Committee 1983 Search Committee - Pharmacy Services 1984 Search Committee - Chairman of Psychiatry 1985-1986 Quality Assurance Committee 1985-1994 UNMC Faculty Senate 1986-1987 Search Committee Director of Psychology 1987-1988 Search Committee Chairman of Pharmacology 1987-1989 University of Nebraska Medical Center Search Committee Member For the Chairman of the Department of Neurology Creighton University College of Medicine 1992 Search Committee Chairman of Psychiatry University of Nebraska Medical Center/Creighton University 1990-1994 Honorary Degrees and Awards Committee
EXTERNAL:
1981-1987 Member, Press Committee, American Academy of Neurology 1988-1993 Member, Public and Professional Information Committee, American Academy of Neurology 1992-1998 Member, Residency Inservice Training Examination (RITE) Committee, American Academy of Neurology 1996 Chairman, Nominating Committee, Parkinson Study Group 1996-1997 Member, Publications Committee, Parkinson Study Group 2001 Member, External Review Committee, Department of Neurology, Uniformed Services University of the Health Sciences 2003-2004 Chairman, Nominating Committee, Parkinson Study Group 2003-2010 Chairman, Continuing Medical Education Committee, Movement Disorders Society 2003-present Member, Research Committee on Parkinsonism and Related Disorders, World Federation of Neurology 2005-2008 Member, Executive Committee, Parkinson Study Group 2005-present Member, Education Committee, We MOVE 2005-2009 Member, Center Review Board, National Parkinson Foundation 2006-2010 Member, Budget Committee, Parkinson Study Group 2006-2012 Chairman, Nominating Committee, Research Committee on Parkinsonism and Related Disorders, World Federation of Neurology 2007-2010 Member, Congress Scientific Programming Committee, Movement Disorders Society
52 RFPfeiffer
2007-2008 Chairman, Nominating Committee, Parkinson Study Group 2008-2010 Member, Site Selection Committee, Parkinson Study Group 2009-2012 Member, Scientific Review Committee, Parkinson Study Group 2009-2011 Chair, Other Non-motor Subgroup, NINDS Parkinson’s Disease Common Element Working Group 2009-present Member, Clinical and Scientific Advisory Board, National Parkinson Foundation 2010-2012 Vice Chair/Chair Elect, Movement Disorders Section, American Academy of Neurology 2010-present Chair, Clinical Study Oversight Committee, Parkinson’s Progression Markers Initiative 2012-present Chair, Movement Disorders Section, American Academy of Neurology 2012 Member, Patient Education Task Force, Movement Disorder Society
FELLOWS/GRADUATE STUDENTS TRAINED:
None
RESEARCH AND OTHER EXTERNAL SUPPORT:
Grant/Contract Support (Current)
Project: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Pharmacodynamics, Efficacy and Safety of RM-131 Administered to Patients with Parkinson’s Disease and Chronic Constipation Dissatisfied with Current Therapy. Date: 2013-present Source: Parkinson Study Group/Michael J Fox Foundation/ Rhythm Pharmaceuticals Study Primary Investigator Chair, Steering Committee
Project: Follow-Up of Persons with Neurologic Diseases (FOUND) Date: 2005-present Source: The Parkinson Institute Institutional Primary Investigator
Grant/Contract Support (Pending):
None currently
Grant/Contract Support (Past):
Project: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Effect of Rotigotine on Motor Symptoms in Patients with Advanced Parkinson’s Disease with Motor Fluctuations and Gastroparesis. Date: 2012-2013 Source: UCB Pharma Institutional Primary Investigator
53 RFPfeiffer
Project: An Investigation of Cogane (PYM50028), an Oral Neurotrophic Factor Inducing Drug: a Potential Early-Stage Novel Therapy for Parkinson’s Disease Date: 2011-2013 Source: Phytopharm Institutional Primary Investigator
Project: A Pilot, Phase II Double-Blind, Placebo-Controlled Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients with early Parkinson’s Disease (STEADY-PD) Date: 2009-2011 Source: Michael J Fox Foundation/Northwestern Dixon Foundation/Parkinson Study Group Institutional Primary Investigator
Project: A Longitudinal Observational Follow-up of the PRECEPT Study Cohort (PostCEPT) Date: 2006-2011 Source: Parkinson Study Group Institutional Primary Investigator
Project: Parkinson’s Research: The Organized Genetics Initiative (PROGENI) Date: 1998-2011 Source: NIH/Parkinson Study Group Institutional Primary Investigator Co-Chair, Steering Committee (2008-2011)
Project: Effects of Coenzyme Q10 in Parkinson Disease – Phase 3 (QE3) Date: 2008-2011 Source: NIH/Parkinson Study Group Institutional Primary Investigator
Project: A Two-Year, Open-Label, Randomized, Parallel-Group, Blinded Assessment, Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in early Parkinson’s Disease Patients Date: 2005-2011 Source: Boehringer Ingelheim Institutional Primary Investigator
Project: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 5-Arm, Parallel-Group Trial to Assess Rotigotine Transdermal System Dose Response in Subjects with Advanced-Stage Parkinson’s Disease Date: 2008-2008; 2010-2011 Source: Schwarz/UCB Institutional Primary Investigator
Project: Spectroscopy in Parkinson Disease (SPIN-PD) Date: 2010 Source: Molecular Biometrics/Parkinson Study Group Institutional Primary Investigator
Project: Consortium on Risk for Early-Onset PD (CORE-PD) Date: 2006-2010 Source: NIH/Columbia University Institutional Primary Investigator
54 RFPfeiffer
Project: A Phase II Randomized, Double-Blind, Placebo-Controlled Dose Response Study of the Efficacy, Safety, and Tolerability of Fipamezole as an Oromucosal Fast Dissolving Tablet in the Treatment of Parkinson’s Disease Patients Date: 2008-2009 Source: Santhera Institutional Primary Investigator
Project: A Long-Term, Double-Blind, Randomized, Parallel-Group, Carbidopa/Levodopa Controlled, Multi-Center Study to Evaluate the Effect of Stalevo in Patients with Parkinson’s Disease Requiring Initiation of Levodopa Therapy (STRIDE-PD) Date: 2005-2009 Source: Novartis Institutional Primary Investigator
Project: Study of Antidepressants in Parkinson’s Disease (SAD-PD) Date: 2006-2008 Source: NIH/University of Rochester Institutional Primary Investigator
Project: A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s disease Date: 2007-2008 Source: Boehringer Ingelheim Institutional Primary Investigator
Project: An Open-Label Multicenter Study of the Continued Safety of Istradefylline (KW-6002) in Subjects with Parkinson’s Disease Who Have Recently Completed One Year of treatment With Istradefylline. Date: 2006-2008 Source: Kyowa Institutional Primary Investigator
Project: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson’s Disease Patients with Motor Fluctuations Date: 2007-2008 Source: Eisai Institutional Primary Investigator
Project: Investigating Effects of Short-Term Treatment with Pramipexole or Levodopa on [123I] β-CIT SPECT Imaging in Early Parkinson’s Disease (INSPECT) Date: 2005-2007 Source: Institute for Neurodegenerative Diseases/Boehringer Institutional Primary Investigator
Project: A Two-week Open-label Trial of Tegaserod (Zelnorm) in Patients with Constipation Associated with Parkinson’s Disease Date: 2006-2007 Source: Novartis Co-Principal Investigator
55 RFPfeiffer
Project: An Open-Label, Multicenter, Multinational, Follow-Up Study to Evaluate the Long- Term Safety and Maintenance of Efficacy of Sarizotan in Parkinson Patients with L-Dopa- Induced Dyskinesia (SPIRID-O). Date: 2003-2006 Source: Merck (Germany) Institutional Primary Investigator
Project: A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter, Fixed Dose-Response Study to Evaluate the Efficacy and Safety of 10, 20, and 40 mg/d Oral Doses of KW-6002 (Istradefylline) as Treatment for Parkinson’s Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy Date: 2004-2005 Source: Kyowa Institutional Primary Investigator
Project: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients with Early Parkinson’s Disease (PRECEPT). Date: 2002-2005 Source: Cephalon/Parkinson Study Group Institutional Primary Investigator
Project: An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of "Off" Episodes in Patients with "On-Off" or "Wearing-Off" Effects Associated with Late Stage Parkinson's Disease. Date: 2000-2005 Source: Mylan/Bertek Institutional Primary Investigator
Project: PNU-95666E: Open-label, Long Term, Flexible Dose Study of Safety, Tolerability, and Therapeutic Response in Patients with Parkinson's Disease Date: 2000-2004 Source: Pharmacia/Pfizer Institutional Primary Investigator
Project: A Multi-Center, Open-Label Trial to Assess Subject Preference of PARCOPA (Carbidopa/Levodopa) Orally Disintegrating Tablets Compared to Conventional Tablets in Subjects with Stable Parkinson’s Disease Date: 2004-2004 Source: Schwarz Institutional Primary Investigator
Project: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Assess the Clinical Benefit of Midodrine Hydrochloride in Patients with Neurogenic Orthostatic Hypotension. Date: 2003-2004 Source: Shire Institutional Primary Investigator
Project: The Long Term Impact of Initiating Pramipexole versus Levodopa in Early Parkinson’s Disease. The CALM-PD Cohort Study Date: 2002-2004 Source: Pharmacia/Parkinson Study Group Institutional Primary Investigator
56 RFPfeiffer
Project: A 4-Week, Multicenter, Open-Label, Single Arm Study Assessing Tolerability of Triple Combination (TC) in Parkinson’s Disease Patients Who Experience End of Dose Wearing Off with Levodopa (SELECT-TC). Date: 2003-2004 Source: Novartis Institutional Primary Investigator
Project: A Multicentre, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Dose-Finding Study to Investigate the Anti-Dyskinetic Efficacy and Safety of Sarizotan in Parkinson Patients with L-Dopa-Induced Dyskinesia (SPIRID). Date: 2002-2003 Source: Merck (Germany) Institutional Primary Investigator
Project: A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety and Tolerability of Sumanirole versus Placebo or Ropinirole in Patients with Parkinson’s Disease. Date: 2002-2003 Source: Pharmacia Institutional Primary Investigator
Project: A Bi-National, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of TV-1203/Carbidopa Dispersable Tablets in Advanced Parkinson’s Disease (PD) Patients with Motor Fluctuations Treated with Chronic Levodopa/Carbidopa Therapy. Date: 2001-2003 Source: Teva/Parkinson Study Group Institutional Primary Investigator
Project: A Multicenter, Randomized, Double-Blind, Parallel Group Study Comparing TV- 1203/Carbidopa Dispersible Tablets with Levodopa/Carbidopa (LD/CD) Tablets in Advanced Parkinson's Disease (PD) Patients with Response Fluctuations. Date: 2000-2002 Source: Teva/Parkinson’s Study Group Institutional Primary Investigator
Project: PNU-95666E: Double-blind, Placebo-controlled, Dose-Response Study of Tolerability, Safety, and Efficacy in Patients with Early Parkinson's Disease Date: 2000-2002 Source: Pharmacia & Upjohn Institutional Primary Investigator
Project: A Prospective, Randomized, Placebo-Controlled, Parallel Groups Study of the Continued Efficacy and Safety of Subcutaneous Injections of Apomorphine in the Treatment of “Off” Episodes in Patients with “On/Off” of “Wearing-off” Effects Associated with Late Stage Parkinson’s Disease After Apomorphine Use for at Least a Three Month Duration. Date: 2001-2002 Source: Mylan/Bertek Institutional Primary Investigator
Project: Comparison of the Agonist Pramipexole vs. Levodopa on Motor Complications in Parkinson’s Disease (CALM-PD) Date: 1996-2001 Source: Pharmacia & Upjohn/Parkinson Study Group
57 RFPfeiffer
Institutional Primary Investigator
Project: A Phase III Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Effect of Riluzole 50 MG BID or 100 MG BID on the Progression of Parkinson's Disease in Patients Treated with L-dopa or Dopamine Agonist Date: 1999-2001 Source: Aventis (Rhône-Poulenc Rohrer) Institutional Primary Investigator
Project: A Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Tolerability and Effect of Entacapone in Parkinson's Disease Patients with Early End-of Dose Wearing Off Treated with Levodopa/Carbidopa. Date: 2000-2001 Source: Novartis Institutional Primary Investigator
Project: A Phase III Multicenter, Double Blind, Parallel-Group Placebo Controlled Study of the Effect on the Progression of Parkinson’s Disease of Riluzole 50 mg BID or 100 mg BID for Two Years in 1050 Patients. Date: 1998-2001 Source: Aventis (Rhone-Poulenc-Rohrer) Institutional Primary Investigator
Project: A Double-Blind, Placebo-Controlled Study of the Effect of Recombinant Human Neurotrophin-3 (NT-3) on Bowel Function in Patients with Parkinson’s Disease Date: 1998-2000 Source: Regeneron Principal Investigators: Eamonn Quigley and Ronald Pfeiffer
Project: PNU-95666E: Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacodynamic, and Pharmacokinetic Study of Patients with Moderate to Advanced Parkinson Disease Date: 1997-1998 Source: Pharmacia & Upjohn Institutional Primary Investigator
Project: Open-Label Study to Identify the Reasons for TASMAR Dosage Regimen Changes in Fluctuating Parkinson's Disease Patients Date: 1998 Source: Roche Institutional Primary Investigator
Project: A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study for the Safety, Tolerability and Efficacy of Daily, Oral Doses of Remacemide Hydrochloride in Subjects with Early Parkinson’s Disease (RAMP) Date: 1997-98 Source: Astra Merck/Parkinson Study Group Institutional Primary Investigator
Project: Neuroprotective Effect of Pramipexole on Dopamine Neurons Exposed to CSF of Parkinson’s Patients Date: 1997-98 Source: Pharmacia & Upjohn Co-Investigator
58 RFPfeiffer
Primary Investigator: Ruyi Hao, MD, PhD
Project: Pramipexole: Safety, Tolerability, Efficacy, and Pharmacokinetic/ Pharmacodynamic Study in Levodopa Treated Parkinson’s Disease Patients of African, Asian and Hispanic Heritage (PRIME) Date: 1997 Source: Pharmacia & Upjohn/Parkinson Study Group Institutional Primary Investigator
Project: Long Term Safety Study of Open-Label Pramipexole in Treated Parkinson’s Disease Patients of African, Asian and Hispanic Heritage (LT-PRIME) Date: 1997-98 Source: Pharmacia & Upjohn/Parkinson Study Group Institutional Primary Investigator
Project: Cabergoline in Treatment of Parkinson Disease: Long-Term Use Date: 1996 Source: Pharmacia & Upjohn Institutional Primary Investigator
Project: Pramipexole and Neurotrophic Factors on DA Neurons Date: 1995-96 Source: Pharmacia & Upjohn Co-Investigator Primary Investigator: Ruyi Hao, MD, PhD
Project: Cabergoline in the Treatment of Parkinson’s Disease: A Placebo-Controlled Study Date: 1995-96 Source: Pharmacia Institutional Primary Investigator
Project: Psychosis and Clozapine in Parkinson’s Disease (PSYCLOPS) Date: 1994-96 Source: Food and Drug Administration, Orphan Products Division/Parkinson Study Group
Project: Double-Blind, Placebo-Controlled, Parallel-group Comparison to Assess the Safety, Tolerance and Efficacy of Pramipexole in Advanced Parkinson's Disease (0679) and to Assess Long-Term Safety With Open-Label Pramipexole (0979) Date: 1993-94 Source: Boehringer Ingelheim Pharmaceuticals Primary Investigator
Project: Blinded Withdrawal of Deprenyl in DATATOP Extension Protocol (BLIND-DATE) Date: 1993-94 Source: University of Rochester/Parkinson Study Group Institutional Primary Investigator
Project: Long-term Use of Cabergoline in Patients who have Completed Phase III Efficacy Study Date: 1993-94 Source: Adria Pharmaceuticals Institutional Primary Investigator
59 RFPfeiffer
Project: A Double-blind, Placebo-controlled, 6 Month Extension Study 101468/055 to Evaluate the Long-term Efficacy and Safety of Ropinirole in Early Parkinsonian Patients Not Receiving Dopaminergic Therapy Date: 1993-94 Source: SmithKline Beecham Pharmaceuticals Institutional Primary Investigator
Project: A Double-Blind, Placebo Controlled, Parallel Group Study of Oral Doses of Ropinirole for Six Months in the Treatment of Early Parkinsonian Patients Date: 1992-94 Source: SmithKline Beecham Pharmaceuticals Institutional Primary Investigator
Project: Triple-Blind Randomized Parallel Study Comparing Sinemet CR (50/200) with Sinemet 25/100 in Parkinson's Disease for Patients on No Prior Levodopa Therapy Date: 1992-93 Source: Merck Sharp & Dohme Institutional Primary Investigator
Project: Cabergoline in the Treatment of Parkinson's Disease Date: 1992-93 Source: Adria Pharmaceuticals Institutional Primary Investigator
Project: ECT for Intractable Parkinson's Disease Date: 1992-93 Source: Psychiatry FDN of Nebraska Co-investigator Primary Investigator - Steven Wengel, M.D.
Project: Environmental Factors and the Prevalence of Parkinson's Disease in Nebraska Date: 1991-94 Source: The American Parkinson Disease Association Primary Investigator
Project: DATATOP Extension Protocol (DATE) Date: 1991-93 Source: Somerset Pharmaceuticals/Parkinson Study Group Institutional Primary Investigator
Project: Deprenyl and Tocopherol Antioxidative Therapy in Parkinson’s Disease Extension Date: 1991-93 Source: National Institutes of Health/Parkinson Study Group Institutional Primary Investigator
Project: Ropinirole 0.5 mg bid or 2.0 mg bid Versus Placebo as Adjunct to L-Dopa in the Treatment of Parkinson's Disease Date: 1991-92 Source: Smith Kline Beecham Pharmaceuticals Institutional Primary Investigator
Project: UNMC Parkinson Disease Brain Bank Date: 1990-93
60 RFPfeiffer
Source: Nebraska Chapter of the American Parkinson Disease Association Primary Investigator Co-investigator - Rodney D. McComb, M.D.
Project: An Open-Label Study of Sinemet CR 25/100 in Parkinsonian Patients without Prior Levodopa Therapy Date: 1990-91 Source: Merck Sharp & Dohme Institutional Primary Investigator
Project: A Double-Blind Study of Two Dose Levels of CQA 206-291 vs Placebo in the Treatment of Patients with Parkinson’s Disease Date: 1989-90 Source: Sandoz Pharmaceuticals Institutional Primary Investigator
Project: American Parkinson Disease Association Information and Referral Center Date: 1988-92 Source: American Parkinson Disease Association Project Director
Project: Deprenyl and Tocopherol Antioxidative Therapy in Parkinson's Disease Date: 1987-91 Source: National Institutes of Health/Parkinson Study Group Institutional Primary Investigator
Project: CQP 201-403 in Parkinson's Disease Date: 1986-87 Source: Sandoz Pharmaceuticals Institutional Primary Investigator
Project: Sinemet CR in Advanced Parkinson's Disease Date: 1986-87 Source: Merck Sharp & Dohme Institutional Primary Investigator
Project: Intrastriatal Adrenal Medulla Grafts: Modulation by Cell Culture and Trophic Factors Date: 1986-87 Source: University of Nebraska Medical Center Seed Grant Primary Investigator
Project: CU32-085 in Parkinson's Disease Date: 1983-85 Source: Sandoz Pharmaceuticals Institutional Primary Investigator
Project: Porcine Stress Syndrome - As a Possible Animal Model of Parkinsonism Date: 1982-83 Source: American Parkinson's Disease Association Cooperating Investigator Principal Investigators: Don Beitz and Don Draper (Iowa State University)
Project: Low Dose Bromocriptine in Parkinsonism
61 RFPfeiffer
Date:1981-83 Source: Sandoz Pharmaceuticals Institutional Primary Investigator
Project: Dexamethasone Suppression Test, Depression and Parkinson's Disease Date: 1981-82 Source: University of Nebraska Hospital Primary Investigator
Project: Dexamethasone Suppression Test, Depression and Parkinson' s Disease Date: 1981-82 Source: United Parkinson Foundation Primary Investigator
VISITING PROFESSORSHIPS AND INVITED LECTURES
June 11, 2014 Wilson’s Disease In: Video Session: Wilson’s Disease and Other “Heavy Metal” Basal Ganglia Disorders 18th International Congress of Parkinson’s Disease and Movement Disorders Stockholm, Sweden
May 14, 2014 Drug-Induced Movement Disorders Resident Seminar Department of Neurology University of Maryland School of Medicine Baltimore, MD
May 14, 2014 Gastrointestinal Dysfunction in Parkinson’s Disease 8th Annual Weiner Memorial Lecture University of Maryland School of Medicine Baltimore, MD
May 10, 2014 Recognition of Autonomic Disturbances in Parkinson’s Disease In: Scientific Session UCB Parkinson’s Disease Speaker Training Meeting Houston, TX
March 29, 2014 Drug-Induced Movement Disorders 21st National Neurology Conference Pakistan Society of Neurology Karachi, Pakistan
March 28, 2014 Autonomic Dysfunction in Parkinson’s Disease 21st National Neurology Conference Pakistan Society of Neurology Karachi, Pakistan
62 RFPfeiffer
March 7, 2014 Gastrointestinal Dysfunction in Parkinson's Disease: Implications on Pharmacological Response In: Scientific Session: Continuous Treatment Strategies in Parkinson's Disease: Current and Future USWorldMeds APOKYN Speaker Training and Parkinson's Disease Scientific Session Coral Gables, FL
February 8, 2014 Recognition and Treatment of Autonomic Disturbances in Parkinson's Disease In: Shaping the Management of Parkinson's Disease: Comprehensive Review of Discoveries and Clinical Trials CME Program Cleveland Clinic and Parkinson Study Group Las Vegas, NV
December 17, 2013 Wilson’s Disease Grand Rounds Department of Neurology University of Southern California Los Angeles, CA
December 10, 2013 Emerging Pharmacotherapeutic Strategies in the Treatment of Parkinson’s Disease In Plenary Session: George Cotzias Symposium – Emerging Conservative Strategies in Parkinson’s Disease 20th World Congress on Parkinson’s Disease and Related Disorders Geneva, Switzerland
October 24, 2013 Parkinson’s Disease and Nonmotor Dysfunction Arkansas Methodist Medical Center Paragould, AR
October 3, 2013Non-Motor Symptoms and PD In Session: Roundtable: Meet the Experts 3rd World Parkinson Congress Montreal, Canada
October 1, 2013Non-Motor Features In Session: Fundamentals of PD 3rd World Parkinson Congress Montreal, Canada
July 12, 2013 Gastrointestinal Dysfunction in Parkinson’s Disease Grand Rounds Department of Neurology Geisel School of Medicine, Dartmouth College Lebanon, NH
April 20, 2013 Panelist In Session: Case Discussion Session: What Will You Do?
63 RFPfeiffer
9th International Congress on Mental Disorders and Other Non-Motor Features in Parkinson’s Disease and Related Disorders Seoul, South Korea
April 20, 2013 Non-cardiovascular Dysautonomia in Parkinson’s Disease In Session: Autonomic Manifestations of Parkinson’s Disease 9th International Congress on Mental Disorders and Other Non-Motor Features in Parkinson’s Disease and Related Disorders Seoul, South Korea
April 19, 2013 Gastrointestinal Dysfunction in Parkinson’s Disease In Session: Olfactory and GI Dysfunction in Parkinson’s Disease 9th International Congress on Mental Disorders and Other Non-Motor Features in Parkinson’s Disease and Related Disorders Seoul, South Korea
April 19, 2013 Ethnic Differences in the Frequency and Type of Nonmotor Features of Parkinson’s Disease In Session: Non Motor Features 9th International Congress on Mental Disorders and Other Non-Motor Features in Parkinson’s Disease and Related Disorders Seoul, South Korea
March 23, 2013 Nonmotor Dysfunction in Parkinson’s Disease: Diagnosis and Management In Session: Bladder Leaks, Sweats, Drools, Sadness and Other Nonmotor Parkinson’s Disease Symptoms: How to Recognize and Treat? American Academy of Neurology Annual Meeting San Diego, CA
March 18, 2013 Hepatology and Neurology In Session: Neurologic Complications of Medical Disease American Academy of Neurology Annual Meeting San Diego, CA
March 18, 2013 Gastroenterology and Neurology In Session: Neurologic Complications of Medical Disease American Academy of Neurology Annual Meeting San Diego, CA
February 13, 2013 Gastrointestinal Dysfunction in Parkinson’s Disease Grand Rounds Department of Neurology Duke University Durham, NC
February 12, 2013 Parkinson’s Disease
64 RFPfeiffer
Dinner Lecture Durham, NC
December 4, 2012 Gastrointestinal Dysfunction in Parkinson’s Disease Grand Rounds Department of Neurology University of Southern California Los Angeles, CA
June 6, 2012 Managing Parkinson’s Disease: Monotherapy Dinner Lecture Traverse City, MI
December 13, 2011 “Non-motor Signs and Symptoms in Parkinson’s Disease” XIX World Congress on Parkinson’s Disease and Related Disorders Shanghai, China
August 23, 2011 “Parkinson’s Disease: State of the Art Management” Parkinson’s Disease: Hot Topics 2011 Memphis, TN
November 6, 2010 “Gastrointestinal Problems in Parkinson’s Disease” 1st Brazilian Summer Symposium on Parkinson’s Disease Praia do Forte, Salvador de Bahia, Brazil
September 30, 2010 “Autonomic Disturbances in Parkinson’s Disease” 2nd World Parkinson Congress Glasgow, Scotland, UK
June 14, 2010 “Gastrointestinal Dysfunction in Parkinson’s Disease” 14th International Congress of Parkinson’s Disease and Movement Disorders Buenos Aires, Argentina
May 27, 2010 “The Evolving Landscape of Parkinson’s Disease: A Case- Based Approach to Treatment” Dinner Lecture Memphis, TN
May 8, 2010 “You Are Now Butterflies, So Soar” Commencement Address Concordia University Nebraska Seward, NE
March 5, 2010 “Parkinson’s Disease and Nonmotor Dysfunction” Neurology Grand Rounds SUNY Downstate Brooklyn, NY
January 12, 2010 “Parkinson’s Disease: The Clinical Spectrum” Tennessee Physical Therapy Association Memphis District Meeting Memphis, TN
65 RFPfeiffer
December 15, 2009 “Gastrointestinal Dysfunction in Parkinson’s Disease” XVIII World Federation of Neurology World Congress on Parkinson’s Disease and Related Disorders Miami, FL
November 11, 2009 “Parkinson’s Disease and Nonmotor Dysfunction” Neurology Grand Rounds University of Mississippi Medical Center Jackson, MS
November 10, 2009 “Dopamine Management in Early to Moderate-to- Advanced Parkinson’s Disease: A Case Study Approach” Dinner Lecture Jackson, MS
August 28, 2009 “Visceral Neurology: Gastrointestinal Dysfunction in Parkinson’s Disease” Chagas Disease Memorial Symposium: Enteric Neuropathies Neurogastroenterology and Motility 2009 Joint International Meeting Chicago, IL
May 12, 2009 “Effective Treatment Strategies in the Management of Parkinson’s Disease” Dinner Lecture Indianapolis, IN
May 5, 2009 “Effective Treatment Strategies in the Management of Parkinson’s Disease” Dinner Lecture Lexington, KY
May 5, 2009 “Case History: Parkinson’s Disease Treatment” Noon Conference – Neurology Residents University of Kentucky Medical Center Lexington, KY
April 7, 2009 “Stalevo and Comtan for the Treatment of Patients with Idiopathic Parkinson’s Disease and End of Dose Wearing Off and Exelon Patch for the Treatment of Mild to Moderate Parkinson’s Disease Dementia” Dinner Lecture Memphis, TN
February 19, 2009 “Effective Treatment Strategies in the Management of Parkinson’s Disease” Dinner Lecture Memphis, TN
66 RFPfeiffer
October 16, 2008 “Stalevo and Comtan for the Treatment of Patients with Idiopathic Parkinson’s Disease and End of Dose Wearing Off” Dinner Lecture Ridgeland, MS
August 19, 2008 “Current Trends in Dopamine Agonist Therapy” Dinner Lecture Memphis, TN
June 24, 2008 “Gastrointestinal Dysfunction” In Teaching Course: Dysautonomia in Parkinson’s Disease: Spectrum, Evaluation and Treatment 12th International Congress of Parkinson’s Disease and Movement Disorders Movement Disorder Society Chicago, IL
April 9, 2008 “Parkinson’s Disease and Nonmotor Dysfunction” Grand Rounds Department of Neurology Yale School of Medicine New Haven, CT
March 1, 2008 “Continuous Drug Delivery for Early-Stage Parkinson’s Disease” Dinner Lecture The Physicians Group-India Memphis, TN
March 1, 2008 “Parkinson’s Disease” 10th Annual General Medicine Conference Jackson-Madison County General Hospital Humboldt, TN
February 23, 2008 “Parkinsonism: Treatment Advances” 25th Annual Black Hills Neurology Symposium Spearfish Canyon, SD
February 22, 2008 “Parkinsonism: Non-motor Dysfunction” 25th Annual Black Hills Neurology Symposium Spearfish Canyon, SD
February 21, 2008 “Neurogastroenterology: A View from Both Ends” 25th Annual Black Hills Neurology Symposium Spearfish Canyon, SD
October 11, 2007 “Respiratory, Gastrointestinal, Urological and Sexual Issues in Parkinson’s Disease” Parkinson Disease Foundation 50th Anniversary Symposium New York, NY
October 5, 2007“Case Presentations”
67 RFPfeiffer
Resident Conference Department of Neurology Indiana University School of Medicine Indianapolis, IN
October 4, 2007“Effective Treatment Strategies in the Management of Parkinson’s Disease” Dinner Lecture Indianapolis, IN
October 4, 2007“Nonmotor Dysfunction in Parkinson’s Disease” Grand Rounds Department of Neurology Indiana University School of Medicine Indiana, IN
October 2, 2007“Advanced Stage Parkinson’s Disease” CME Lecture Milwaukee, WI
August 28, 2007 “Treatment of Parkinson’s Disease” Dinner Lecture Memphis, TN
August 9, 2007 “Update on Parkinson’s Disease: Treatment in Early and Moderate-Advanced Disease” Dinner Lecture Tupelo, MS
May 8, 2007 “Treatment of Parkinson’s Disease” Dinner Lecture Memphis, TN
April 12, 2007 “Update on Parkinson’s Disease: Treatment in Early and Moderate-to-Advanced Disease” Dinner Lecture Hattiesburg, MS
April 3, 2007 “Optimized Levodopa Therapy” Dinner Lecture Memphis, TN
March 30, 2007 “Gastrointestinal Dysfunction in Parkinson’s Disease” Grand Rounds Department of Neurology Case Western Reserve School of Medicine Cleveland, OH
March 22, 2007 “Parkinson’s Disease: Where Does It Begin?” Lecture/Discussion Movement Disorders Journal Club Oregon Health Science University Portland, OR
68 RFPfeiffer
March 21, 2007 “Neurogastroenterology” Grand Rounds Department of Neurology Oregon Health Science University Portland, OR
March 8, 2007 “Managing Motor Complications in Parkinson’s Disease” Dinner Lecture Memphis, TN
February 27, 2007 “Parkinson’s Disease and Nonmotor Dysfunction” Grand Rounds Jackson Madison County Hospital Jackson, TN
January 25, 2007 “A Select Sampling of New Anti-Parkinsonian Therapies” Lecture Neurological Update 2007 (University of Miami) Miami Beach, FL
January 25, 2007 “Gastrointestinal Dysfunction in Parkinson’s Disease” Lecture Neurological Update 2007 (University of Miami) Miami Beach, FL
December 12, 2006 “Enhancing the Effectiveness of Levodopa in Parkinson’s Disease” Dinner Lecture Memphis, TN
November 12, 2006 “Parkinson’s Disease and Nonmotor Dysfunction” Lecture Advances in Managing Diseases of the Central Nervous System: Multiple Sclerosis and Parkinson’s Disease 5th Annual Conference (University of South Florida) White Sulphur Springs, WV
November 6, 2006 “Advances in the Treatment and Management of Parkinson’s Disease” Dinner Lecture Memphis, TN
October 27, 2006 “Treatment of Parkinson’s Disease: Where Are We Now; Where Are We Headed?” Lecture Tri-State Neurology Conference Jackson, MS
October 26, 2006 “Update on Parkinson’s Disease: Treatment in Early and Moderate-To-Advanced Disease” Dinner Lecture Memphis, TN
October 13, 2006 “Parkinson’s Disease and Nonmotor Dysfunction”
69 RFPfeiffer
Lecture 2006 Parkinson’s Disease and Associated Neurologic Disorders Symposium Tallahassee Memorial Neuroscience Center Florida State University Tallahassee, FL
October 7, 2006“Recognizing Unmet Needs in Parkinson’s Disease” Lecture CME Course: Targeting Unmet Needs in the Management of Parkinson’s Disease: New Developments and Implications Dearborn, MI
September 25, 2006 “La Dolce Vita: Listening and Learning with your Physician” Lecture Wellness Day for Professional Church Workers Springfield, VA
September 21, 2006 “New Therapies in Parkinson’s Disease Dinner Lecture Jackson, MS
June 9, 2006 “Ropinirole in the Management of Parkinson’s Disease” Dinner lecture Buffalo, NY
April 14, 2006 “Mirapex in the Management of Parkinson’s Disease” Dinner Lecture Clarksdale, MS
April 11, 2006 “Optimized Levodopa Therapy” Dinner Lecture Memphis, TN
March 20, 2006 “Parkinson’s Disease and Nonmotor Dysfunction” Grand Rounds Department of Geriatric Medicine University of Hawaii Honolulu, HI
February 24, 2006 “Apathy, Withdrawal, and Personality Change in Parkinson’s Disease” Lecture World Parkinson Congress Washington, DC
February 16, 2006 “La Dolce Vita: Listening and Learning with your Physician” Lecture Wellness Day for Professional Church Workers Solana Beach, CA
70 RFPfeiffer
February 15, 2006 “La Dolce Vita: Listening and Learning with your Physician” Lecture Wellness Day for Professional Church Workers Irvine, CA
January 13, 2006 “Gastrointestinal Dysfunction in Parkinson’s Disease” Grand Rounds Department of Neurology University of Virginia Medical School Charlottesville, VA
January 12, 2006 “LRRK2: The Western Nebraska Kindred” “Ropinirole in the Management of Parkinson’s Disease” Dinner Lectures Charlottesville, VA
December 16, 2005 “Parkinson’s Disease and Nonmotor Dysfunction” Grand Rounds Department of Neurology University of Kansas Medical Center Kansas City, KS
November 8, 2005 “Optimized Levodopa Therapy” Dinner Lecture Nashville, TN
October 21, 2005 “Parkinson’s Disease and Nonmotor Dysfunction” Lecture National Parkinson Foundation Leadership Conference San Francisco, CA
April 28, 2005 “Parkinson’s Disease and Nonmotor Dysfunction” Dinner Lecture Neuroscience Roundtable Florida State University College of Medicine Tallahassee, FL
April 7, 2005 “Parkinson’s Disease and Nonmotor Dysfunction” Keynote Speaker 25th Annual Frank N. Low Research Day University of North Dakota School of Medicine Grand Forks, ND
February 2, 2005 “Exploring Movement Disorders: Parkinson’s Disease and Restless legs Syndrome” Dinner Lecture Memphis, TN
January 19, 2005 “Exploring Movement Disorders: Parkinson’s Disease and Restless Legs Syndrome” Dinner Seminar Johnstown, PA
71 RFPfeiffer
November 12, 2004 “La Dolce Vita: Listening and Learning with your Physician” Lecture Wellness Day for Pastors and Principals Waukesha, WI
November 9, 2004 “Off Episodes in Parkinson’s Disease” Dinner Seminar Louisville, KY
September 6, 2004 “Transdermal Dopamine Agonist Treatment of Parkinson’s Disease” Lecture Satellite Symposium 8th Congress of the European Federation of Neurological Societies Paris, France
August 28, 2004 “Other Pharmacological Treatments for Motor Complications” Course Lecture Movement Disorders Society Course: Practical Management of Motor Complications in Parkinson’s Disease Chicago, IL
June 14, 2004 “Gastrointestinal and Urological Dysfunction in Neurodegenerative Disease” Seminar Lecture 8th International Congress of Parkinson’s Disease and Movement Disorders Rome, Italy
May 4, 2004 “New Directions in the Management of Movement Disorders” Dinner Seminar Memphis, TN
April 27, 2004 “Parkinson’s Disease Treatment Update” Dinner Seminar Memphis, TN
March 4, 2004 “Parkinson’s Disease Case Vignettes” Dinner Seminar Memphis, TN
December 16, 2003 “Treatment of Parkinson’s Disease” Dinner Seminar Memphis, TN
December 1, 2003 “Treatment of Parkinson’s Disease” Lunch Seminar Fayetteville, AR
72 RFPfeiffer
November 24, 2003 “Treatment of Parkinson’s Disease” Dinner Seminar Memphis, TN
October 24, 2003 “Treatment of Parkinson’s Disease” Grand Rounds Department of Internal Medicine University of Nebraska Medical Center Omaha, NE
October 7, 2003“Treatment of Parkinson’s Disease” Dinner Seminar Nashville, TN
September 30, 2003 “An Update on Parkinson’s Disease” Dinner Seminar Memphis, TN
September 19, 2003 “Etiology and Pathogenesis of Parkinson’s Disease” Tri-State Neurology Conference Greenville, MS
May 17, 2003 “Parkinson’s Disease” Core Curriculum Lecture American Geriatric Society Annual Meeting Baltimore, MD
May 6, 2003 “Parkinson’s Disease” Inservice Lecture Baptist Trinity Healthcare Memphis, TN
March 4, 2003 “Treatment of Parkinson’s Disease” Dinner Seminar Memphis, TN
December 7, 2002 “Etiology and Pathogenesis of Parkinson’s Disease” Parkinson’s Disease and Restless Legs Syndrome Seminar New York, NY
November 15, 2002 “Case Discussions” Neurological Aspects of Wilson’s Disease Symposium Miami, FL
November 7, 2002 “Parkinson’s Disease” Coalition of Alzheimers and Related Disorders of Northwest Alabama Meeting Florence, AL
April 19, 2002 “Autonomic Dysfunction in Parkinson’s Disease” Dinner Seminar Lecture American Academy of Neurology Annual Meeting Denver, CO
73 RFPfeiffer
February 23, 2002 “Parkinsonism – Diagnosis and Treatment” 19th Annual Black Hills Neurology Seminar Spearfish Canyon, SD
February 22, 2002 “Essential Tremor – Diagnosis and Treatment” 19th Annual Black Hills Neurology Seminar Spearfish Canyon, SD
February 21, 2002 “Encephalopathies – Diagnosis and Treatment” 19th Annual Black Hills Neurology Seminar Spearfish Canyon, SD
June 21, 2001 “Neurological Dysfunction in Gastrointestinal Disease” Lecture World Congress of Neurology London, UK
May 6, 2001 “Autonomic Dysfunction in Parkinson’s Disease” Dinner Seminar Lecture American Academy of Neurology Annual Meeting Philadelphia, PA
April 30, 2001 “Use of the UPDRS in Parkinson’s Disease” Parkinson’s Disease Education Course Struthers Parkinson’s Disease Center Minneapolis, MN
April 30, 2001 “Parkinson’s Disease Research” Parkinson’s Disease Education Course Struthers Parkinson’s Disease Center Minneapolis, MN
October 8, 2000 “Laboratory Evaluation of Movement Disorders” Movement Disorders for the Clinician Mayo Clinic Jacksonville Course Savannah, GA
February 4, 2000 “Gastrointestinal Dysfunction in Parkinson's Disease” Seminar, Alzheimer's and Parkinson's Disease Center Mayo Clinic, Jacksonville Jacksonville, FL
February 1, 2000 “Management of Parkinson's Disease: Case Vignettes” Dinner Seminar Biloxi, MS
January 31, 2000 "Management of Parkinson's Disease: Case Vignettes” Dinner Seminar New Orleans, LA
November 17, 1999 “Management of Parkinson's Disease: Case Vignettes” Dinner Seminar Amarillo, TX
74 RFPfeiffer
November 17, 1999 “Gastrointestinal Dysfunction in Parkinson's Disease” Grand Rounds Covenant Hospital System Lubbock, TX
November 16, 1999 “Management of Parkinson's Disease: Case Vignettes” Dinner Seminar Lubbock, TX
July 28, 1999 “Parkinson’s Disease in the Young Robust” Breakfast Seminar Lecture XIII International Congress on Parkinson’s Disease Vancouver, B.C., Canada
July 21, 1999 “Gastrointestinal Dysfunction in Parkinson's Disease” Grand Rounds, Department of Neurology Brown University Providence, RI
July 8, 1999 “Update on the Management of Parkinson's Disease” North Carolina Academy of Family Physicians Mid-Summer Family Practice Digest Myrtle Beach, SC
June 29, 1999 "Gastrointestinal Dysfunction in Parkinson's Disease" Grand Rounds, Department of Neurology University of Iowa Iowa City, IA
June 25, 1999 "Autonomic Dysfunction in Parkinson's Disease" Grand Rounds, Department of Neurology Wayne State University Detroit, MI
June 24, 1999 "Management of Parkinson's Disease: Case Vignettes" Dinner Seminar Southfield, MI
April 14, 1999 "Management of Parkinson's Disease: Case Vignettes" Dinner Seminar Tallahassee, FL
November 10, 1998 "New Advances in the Treatment of Parkinson's Disease"
Dinner Lecture Memphis, TN
October 10, 1998 “Wilson’s Disease” Breakfast Seminar Lecture 5th International Conference on Parkinson’s Disease and Movement Disorders New York, NY
August 6, 1998 "New Strategies in Treating Parkinson's Disease"
75 RFPfeiffer
Dinner Lecture Memphis, TN
May 20, 1998 “Gastrointestinal Dysfunction in Parkinson’s Disease” Grand Rounds, Department of Neurology SUNY-Brooklyn New York, NY
May 6, 1998 “Gastrointestinal Dysfunction in Parkinson’s Disease” Grand Rounds, Department of Neurology University of Kansas Kansas City, KS
February 21, 1998 “Migraine Headaches: Remedies Old and New” 15th Annual Black Hills Neurology Seminar Spearfish Canyon, SD
February 20, 1998 “Parkinsonism: Medical and Surgical Treatments” 15th Annual Black Hills Neurology Seminar Spearfish Canyon, SD
February 19, 1998 “Parkinsonism: Diagnosis and Medical Treatment” 15th Annual Black Hills Neurology Seminar Spearfish Canyon, SD
February 6, 1998 “Gastrointestinal Dysfunction in Parkinson’s Disease” Grand Rounds, Department of Neurology Medical University of South Carolina Charleston, SC
December 8, 1997 “Management of Parkinson’s Disease: Case Vignettes” Dinner Meeting Birmingham, AL
December 8, 1997 “Treatment of Parkinson’s Disease Grand Rounds, Department of Neurology University of Alabama - Birmingham Birmingham, AL
July 15, 1997 “Management of Parkinson’s Disease: Case Vignettes” Dinner Meeting Kingsport, TN
April 24, 1997 “Management of Parkinson’s Disease: Case Vignettes” Dinner Meeting Mobile Neurological Society Mobile, AL
March 20, 1997 “Parkinson’s Disease and Its Treatment” Annual Conference Veterans Affairs Physician Assistants Association Memphis, TN
February 20, 1997 “Management of Parkinson’s Disease: Case Vignettes”
76 RFPfeiffer
Dinner Meeting Memphis, TN
November 16, 1996 “Medical Management of Parkinson’s Disease” Annual Meeting American Society of Consultant Pharmacists Nashville, TN
October 10, 1996 “Management of Parkinson’s Disease: Case Vignettes” Dinner Meeting Nashville, TN
October 3, 1996 “Management of Parkinson’s Disease: Case Vignettes” Dinner Meeting Knoxville, TN
August 20, 1996 “Gastrointestinal Dysfunction in Parkinson’s Disease” Grand Rounds, Department of Neurology University of Alabama-Birmingham Birmingham, AL
May 17, 1996 “Clinical Features of Dystonia” Symposium: Dystonia Methodist Hospital Memphis, TN
March 25, 1996 “The Pathologic Basis and Clinical Spectrum of Neurological Diseases with Gastrointestinal Dysfunction” Breakfast Seminar Lecture American Academy of Neurology Annual Meeting San Francisco, CA
May 12, 1995 “The Pathologic Basis and Clinical Spectrum of Neurological Disease with Gastrointestinal Dysfunction” After Dinner Seminar Lecture American Academy of Neurology Annual Meeting Seattle, WA
May 4, 1995 “New Concepts in the Pharmacological Management of Parkinson’s Disease” St Francis/University of Tennessee Symposium Memphis, TN
March 13, 1995 “Parkinson’s Disease” Family Practice Review Course University of Tennessee, Memphis Memphis, TN
February 4, 1995 “Parkinson’s Disease" South Dakota Academy of Family Practice Lead, SD
February 4, 1995 “Peripheral Neuropathy" South Dakota Academy of Family Practice
77 RFPfeiffer
Lead, SD
February 4, 1995 “Movement Disorders” South Dakota Academy of Family Practice Lead, SD
November 17, 1994 “Clinical Aspects of Movement Disorders” Department of Biomedical Engineering University of Tennessee, Memphis Memphis, TN
November 11, 1994 “Gastrointestinal Dysfunction in Parkinson’s Disease” Breakfast Seminar Lecture 3rd International Congress of Movement Disorders Orlando, FL
November 1, 1994 “Management of Parkinson’s Disease” Five County Medical Society Clarksdale, MS
October 22, 1994 “Management of Parkinson’s Disease” Neurology for the Primary Care Practitioner - Series V Program Colorado Neurological Institute Denver, CO
October 22, 1994 “Essential Tremor and Look-alikes” Neurology for the Primary Care Practitioner - Series V Program Colorado Neurological Institute Denver, CO
October 21, 1994 “Managing Parkinson’s Disease: The Rational use of combination therapy” Dinner Seminar Denver, CO
February 26, 1994 “Parkinson’s Disease: Gastrointestinal Dysfunction.” Black Hills Neurology Seminar Spearfish, SD
February 25, 1994 “Parkinsonism: Diagnosis and Treatment.” Black Hills Neurology Seminar Spearfish, SD
February 24, 1994 “Movement Disorders: From Horses to Zebras.” Black Hills Neurology Seminar Spearfish, SD
December 3, 1993 “Comparison of Bromocriptine to Pergolide.” Athena Neurosciences Faculty Review Meeting. Atlanta, GA
November 30, 1993 “Gastrointestinal Dysfunction in Parkinson’s Disease.”
78 RFPfeiffer
Grand Rounds, Department of Neurology University of Oklahoma Health Science Center Oklahoma City, OK
November 1, 1993 “Diagnosis and Treatment of Parkinson’s Disease.” Dept. Anatomy & Cell Biology Seminar. University of Nebraska Medical Center Omaha, NE
October 6, 1993"Gastrointestinal Dysfunction in Parkinson's Disease." Grand Rounds, Department of Neurology University of Texas Southwestern Medical Center Dallas, TX
Sept. 23, 1993 "Gastrointestinal Symptoms in Parkinson's Disease." Interdisciplinary International Symposium on Gastrointestinal Dysfunction in Neurological Diseases Omaha, NE
Sept. 14, 1993 Management of Parkinson's Disease. Cass County Hospital Medical Staff Atlantic, IA
May 4, 1993 "Parkinson's Disease" Lutherans of Greater Omaha Omaha, NE
April 14, 1993 "Gastrointestinal Dysfunction in Parkinson's Disease" Visiting Professor China-Japan Friendship Hospital Beijing, China
October 31, 1992 "Non-Pharmacologic Aspects of Parkinson's Disease" Symposium: Recognition & Management of Parkinson's Disease for the Primary Care Physician University of Kansas Medical Center Kansas City, KS
October 30, 1992 "Gastrointestinal Dysfunction in Parkinson's Disease" Grand Rounds Department of Neurology University of Kansas Medical Center Kansas City, KS
January 8, 1992 "Gastrointestinal Dysfunction in Parkinson's Disease" Movement Disorder Conference Department of Neurology Robert Wood Johnson Medical Center New Brunswick, NJ
January 8, 1992 "Gastrointestinal Dysfunction in Parkinson’s Disease Grand Rounds Department of Neurology University of Medicine & Dentistry of New Jersey
79 RFPfeiffer
Newark, NJ
Nov. 22-23, 1991 "Treatment of Moderately Advanced Parkinson's Disease" Neurology Update 1991: Parkinson's Disease, Drug- Induced Movement Disorders and Ischemic Stroke Department of Neurology University of Iowa Medical Center Iowa City, IA
Sept. 12, 1991 "Management of Parkinson's Disease" Fremont Golf Club Fremont, NE
August 29, 1991 "Treatment of Neurological Disorders in a Family Practice Setting: Great Plains Regional Medical Center North Platte, NE
August 28, 1991 "Diagnosis and Treatment of Parkinson's Disease" Downtown Rotary Club Omaha, NE
August 17, 1991 "Diagnosis and Treatment of Parkinson's Disease" Midlands Community Hospital Papillion, NE
August 15, 1991 "Diagnosis and Treatment of Parkinson's Disease" Health America-Lincoln Lincoln, NE
April 21, 1991 "Initiating & Optimizing Therapy" Symposium: New Concepts on the Management of Parkinson's Disease Boston, MA
April 4, 1991 "Understanding and Dealing With Gastrointestinal Problems in Parkinson's Disease" Symposium: Kansas City Chapter, American Parkinson's Disease Association Kansas City, KS
March 14, 1991 "Parkinson's Disease: Causes, Treatments and Research" New Cassel Retirement Center Omaha, NE
March 8, 1991 "Optimalization of Sinemet Therapy" Keystone, CO
January 31, 1991 "Management of Parkinson's Disease" Sioux Falls, SD
January 23, 1991 "Management of Parkinson's Disease" McCook, NE
80 RFPfeiffer
December 6, 1990 "Sinemet CR and Parkinson's Disease" University of British Columbia Vancouver, British Columbia
February 19, 1990 "New Therapeutic Strategies in Parkinson's Disease" Midlands Neuroscience Chapter UNO, Omaha, NE
February 15, 1990 "Parkinson's Disease: Etiology and Clinical Presentation" Continuing Health Education Iowa Western Community College Council Bluffs, IA
February 15, 1990 "Parkinson's Disease: Treatment and Research" Continuing Health Education Iowa Western Community College Council Bluffs, IA
November 4, 1989 "Current and Future Approaches to the Treatment of Parkinson's Disease" Gerontology Program Riverside Country Club, Grand Island, NE
Sept. 27, 1989 "Parkinson's Disease" Nursing Inservice, Good Samaritan Center Auburn, NE
Sept. 26, 1989 "Current and Future Approaches to the Treatment of Parkinson's Disease" Grand Rounds, Family Practice Program San Jacinto Methodist Hospital Houston, TX
Sept. 26, 1989 "Current and Future Approaches to the Treatment of Parkinson's Disease" Family Practitioner Society Colorado Springs, CO
Sept. 15, 1989 "Reflex Sympathetic Dystrophy" Intracorp Breakfast Seminar Omaha, NE
Sept. 9, 1989 "Possible Causes of Parkinson's Disease" American Parkinson's Disease Association - Nebraska Chapter Annual Symposium Omaha, NE
August 31, 1989 "The Treatment of Parkinson's Disease" Grand Rounds Department of Neurology University of Missouri, Columbia, MO
August 18, 1989 "Current and Future Approaches to the Management of Parkinson's Disease"
81 RFPfeiffer
Medical Staff Conference Good Samaritan Hospital Kearney, NE
Feb. 14-17, 1989 Lectures: “Clinical Features and Diagnosis of Parkinson’s Disease” “Conventional Therapy of Parkinson’s Disease” Symposium: Parkinson’s Disease and Other Movement Disorders Vail, CO
April 8, 1988 "Parkinson's Disease" Lutheran Men of Omaha Anthony's Restaurant Omaha, NE
January 16, 1988 "Current & Future Approaches to the Treatment of Parkinson's Disease" Neurology Colloquium at Venice Inn Omaha, NE
December 11, 1987 "Current & Future Approaches to the Treatment of Parkinson's Disease" University of Kansas Kansas City, KS October 27, 1987 "Parkinson's Disease" Omaha Mid-West Clinical Society Red Lion Inn Omaha, NE
October 27, 1987 “Transmissible Dementias “ Omaha Mid-West Clinical Society Red Lion Inn Omaha, NE
Sept. 25, 1987 "Current & Future Approaches to the Treatment of Parkinson's Disease" Good Samaritan Hospital Kearney, NE
Sept. 16, 1987 "Current & Future Approaches to the Treatment of Parkinson's Disease" St. Vincent’s Hospital Billings, MT
May 22, 1987 "Parkinson's Disease: An Update" Department of Education Labette County Medical Center Parsons, KS
May 14, 1987 "Current and Future Treatment of Parkinson's Disease" Greater Kansas City Chapter American Parkinson's Disease Association Kansas City, MO
82 RFPfeiffer
May 14, 1987 "Current and Future Treatment of Parkinson's Disease" Academy of Health Professions Kansas City, MO
May 14, 1987 "Mental Changes in the Patient with Parkinson's Disease" Academy of Health Professions Kansas City, MO
April 23, 1987 "Parkinson's Disease" Mid-American Congress on Aging 4th Annual Conference - Red Lion Inn Omaha, NE
January 20, 1987 "Current Concepts in Parkinson's Disease" Medical Education Program Poudre Valley Hospital Ft. Collins, CO
January 8, 1987 "Parkinson's Disease" Cass County Alzheimers Support Group Cass County Memorial Hospital Atlantic, IA
July 22, 1986 "Parkinson's Disease" Elkhorn Manor Elkhorn, NE June 26, 1986 "Blepharospasm/Torticollis" Neurologically Based Movement Disorders Workshop Bellevue Public Library Bellevue, NE
May 13-14, 1986 "Current Concepts in Parkinson's Disease" Lake Jackson, TX
April 17, 1986 "Parkinson's Disease - Guidelines for Patients" Parkinson's Disease Informational Workshop Bellevue Public Library Bellevue, NE
April 9, 1986 "Current Concepts of Parkinson's Disease" Beaumont, TX
February 11, 1986 "Current Concepts of Parkinson's Disease" St. Joseph's Hospital Concordia, KS
December 9, 1985 "Current Concepts of Parkinson's Disease" University of Utah Salt Lake City, UT
November 13, 1985 "Current Concepts of Parkinson's Disease" Hall County Medical Society
83 RFPfeiffer
Grand Island, NE
October 16, 1985 "Current Concepts of Parkinson's Disease" Cheyenne, WY
May 31, 1985 "Current Management of Parkinson's Disease" Queens Medical Center Honolulu, HI
May 20, 1985 "Mental Status Changes in Parkinson's Disease" American Parkinson Disease Association Symposium Kansas City, MO
May 15, 1985 "Parkinson's Disease: Problems in Diagnosis and Management" Torrance Memorial Hospital Medical Center Torrance, CA
March 19, 1985 "Clinical Management of Parkinson's Disease" Menorah Medical Center Kansas City, MO
January 21, 1985 "Current Concepts in the Management of Parkinson's Disease" Encino Hospital Encino, CA
January 15, 1985 "Current Concepts in the Management of Parkinson's Disease" Baptist Medical Center Kansas City, MO
December 5, 1984 "Current Concepts of Parkinson's Disease" Kaiser Permanente Hospital Bellflower, CA
October 26, 1984 "Medical Management of Parkinson's Disease" Grossmont District Hospital La Mesa, CA
October 3, 1984"Mesulergine: 18 Months' Experience" Symposium on Parkinson's Disease Bermuda
February 17, 1984 "Newer Drugs in the Treatment of Parkinsonism" Green Valley, AZ Green Valley Parkinson Support Group (Arizona Parkinson Awareness Week)
February 17, 1984 "Newer Drugs in the Treatment of Parkinsonism" University of Arizona Health Sciences Center Neurology Grand Rounds (Arizona Parkinson Awareness Week)
84 RFPfeiffer
February 13, 1984 "Newer Drugs in the Treatment of Parkinsonism" Methodist Hospital Omaha, Nebraska
February 8, 1984 "Immunologic Aspects of Multiple Sclerosis" Methodist Hospital Omaha, NE
December 6, 1983 "Parkinson's Disease and Therapy" Iowa State University College of Veterinary Medicine Ames, IA
November 12, 1983 "Facial Tic and Blepharospasm" Nebraska Methodist Hospital - Grand Rounds Omaha, NE
October 10, 1983 "Parkinson's Disease" Westside Lions Club Omaha, NE
August 10, 1983 "Epilepsy" Omaha Manor Omaha, NE
August 9, 1983 “Parkinson's Disease" Sunderman Nursing Home Seward, NE
August 17, 1982 "Parkinson's Disease" St. Francis Hospital Grand Rounds Wichita, KS
July 9, 1982 "Parkinson's Disease" Grand Rounds Jennie Edmundson Hospital Council Bluffs, IA
June 24, 1982 "Parkinson's Disease" Topeka VAH Grand Rounds Topeka, KS
June 23, 1982 "Parkinson's Disease" Neurology Grand Rounds KCVAH Kansas City, MO
June 2, 1981 "Parkinson's Disease" County Medical Society York, NE
March 16, 1981 "Parkinson's Disease" Grand Rounds: Clarinda Hospital Clarinda, IA
85 RFPfeiffer
January 16, 1981 "Parkinson's Disease" Grand Rounds: Good Samaritan Hospital Kearney, NE
November 22, 1980 "Treatment of Parkinson's Disease" Northwest Medical Society Chadron, NE
86